&21),'(17,$/$1'[ZIP_CODE],(7$5<
&/,1,&$/678'<[ZIP_CODE]&2/
7UHDWPHQWRI3URWHLQXULD'XHWR7UHDWPHQW5HVLVWDQWRU7UHDWPHQ W
,QWROHUDQW,GLRSDWKLF)RFDO6HJPH QWDO*ORPHUXORVFOHURVLV
$3URVSHFWLYH6WXG\RI$FWKDU32'2&<7(
3URWRFRO1XPEHU 01.
'DWHRI2ULJLQDO3URWRFRO  'HFHPEHU
'DWHRI3URWRFRO$PHQGPHQW $SULO
'DWHRI3URWRFRO$PHQGPHQW $XJXVW
'DWHRI3URWRFRO$PHQGPHQW 2FWREHU
'DWHRI3URWRFRO$PHQGPHQW -XQH
0DOOLQFNURGW$5'//&
865RXWH 
%HGPLQVWHU1-8QLWHG6WDWHVRI$PHULFD/$5
Mallinckrodt ARD LLC  
MNK142 [ADDRESS_1250833] of changes 
from Amendment 2.1 to Amendment 3.0.  
ï‚·The title page was updated to reflect the regulatory requirement to use the
Mallinc krodt ARD LLC corporate headquarters address in Bedminster, New Jersey.
ï‚·Change d enrolled population from 236 to 60 subjects.
ï‚·Removed the double -blind, placebo -controlled randomization maintenance period
(week 2 6, including removing the forced taper starting at Week  26, to Week  50) to
extend the open label/open -label extension period (Week 26 to Week 50).
ï‚·Changed primary objective from confirmation of efficacy to confirmation of safety
and tolerability.
ï‚·Changed primary endpoints to
ï€­ Severity and frequency of AEs
ï€­ Changes in physical findings
ï€­ Changes in clinical laboratory findings
ï€­ Changes in v ital signs
ï‚·Removed all secondary objectives and endpoints.
ï‚·Removed all exploratory objectives in Amendment 2.1. Replaced with 
ï‚·Removed all exploratory endpoints from A mendment 2.1. Replaced with
ï€­ 
 
 
 
 
 
 
 
 
 

Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 3 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
    
  
  
  
  
ï‚· Descriptive statistics only.  
ï‚· Reformatted to new Mallinckrodt format.  Section numbering , table and figure 
numbering,  and inter nal section references were adjusted in the amended protocol  
 
PROTOCOL AMENDMENT 2.1 DATED 12 OCTOBER 2017  
Summary of Changes in Amendment 2.1  
 
The following changes from p rotocol Amendment 2 to Amendment 2.1 where made:  
1. The title page was updated to reflect the regulatory requirement to use the Mallinckrodt  
ARD, Inc. corporate headquarters address in Hazelwood , Missouri.  
2. Section 2 (Contacts) was deleted. This information will be supplied in the Study 
Operations Manual with updates to that document as needed. The Emergency Contacts 
list in the Study Operations Manual will be revised to remove  
 as medical monitors.  will remain as regional 
medical monitors. Section numbering and inter nal section references were adjusted in the 
amended protocol based on this deletion.  
3. International Council  on Harmonisatio n was changed to International Council for  
Harmonisation  globally.  
4.  Week 24 is noted as Visit 8 throughout the protocol.  
5. Corresponding appropriate changes were made to the study synopsis (Section 1.1). 
6. The abbreviation  was added to abbreviation list.  was used 
throughout the protocol.  
7. Serum sampling for cortisol determination was removed as an safety assessment from 
Table 1 (Schedule of Study Events, Section 1.4), Section 8 (Procedures), Section 10 
(Safety Assessments and Procedures), Section 10.7 (Clinical Laboratory Tests, HbA1c, 
, IGRA, Urinalysis, and Pregnancy Tests), and 
Section 24.1 (Attachment 1: Clinical Laboratory Tests). It was recognized that there is no 
endpo int associated with the assessment and  
 
. 
8. on was added to screening at Visi t 1. Table 1  (Schedule of Study 
Events, Section 1.4) was revised to add a separate row for with a determination 

Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 4 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 indicated at Visit 1. Section 8 (Procedures) was revised to include the  
determination to the Visit 1.  
9. The timing of the Baseline Visit/Visit [ADDRESS_1250834] had no treatment at 
Screening Visit/Visit 1 to â€œEligibility is confirmed and IMP is on -siteâ€ in  Table 1  
(Section 8.2).  
10. Willingness to undergo  
, was added to Inclusion Criterion 5 ( Section 6.1). Table 1  (Schedule of Study 
Events, Section 1.4) and Section 6.1 (Inclusion Criteria) were revised to reflect this new 
criterion. Section 13 (Procedures) was revised to include the  at Visit 1.  
11. Male contraception was remov ed from Inclusion Criterion 4 ( Section 6.1). There is no 
relevant data to indicate a teratogenic, or genotoxic risk of ACTH peptides in Acthar.  
12. The qualifying urine  protein creatinine ratio in Inclusion Criterion 6 ( Section 6.1) was 
changed from greater than 3.5 mg/mg to greater than 3.0 mg/mg.   
13. Cyclophosphamide was added to medications prohibited 24 weeks before screening at 
Visit 1 Exclusion Criterion 24 (Column 1, Table 2 ) was revised to add 
"cyclophosphamide" to the column. Cyclophosphamide was added to prohibited 
medications because of its long pharmacodynamic half -life. The title to Table 2  was 
inadvertently changed from â€œScreening Visit/Visit 1â€ to â€œScreening Visit/Visit.â€  
14. The title to  Table 2  was corrected from â€œS creening Visit/Visitâ€ to â€œScreening Visit/Visit 
1.â€ 
15. Mathematical operators were removed globally for better readability. Inadvert ent errors 
in Exclusion Criterion 27 ( Section 6.2) were made in the conversion of mathematical 
symbols to text  in Protocol Amendment 2.0; these have been corrected .  
16. The definition of screen failures was revised to allow only one repeat measurement 
(Section 6.3 and Section 8.1). The following text was added to Section 8.1: â€œA screening 
procedure can be repeated only once; if the repeat procedure continues to be 
exclusionary, the subject will be a screen failure.â€  
17. Prohibited concomitant medications ( Section 7.1) were revised to include any long -acting 
corticotropin, other than Acthar, and to allow intraocular immunosuppressive 
medications.  
18. Expanded the information to be conveyed during the IXRS contact ( Section 9.1). 
Replaced the text â€œThe investigator or designee must contact [CONTACT_893153]â€™s statusâ€ with the text â€œ  
 during the 
IXRS contact; appropriate kit assignment will be made following this determination.â€  
19. Time durations in Table 5  (Section 9.3, Dosing Procedures) were revised in Column 1. 
Footnotes b and c to  Table 5  were changed from Week 23 to Week 24.  
20. Dosing procedures ( Section 9.3) were updated to include information regarding 
restrictions on dosing. The text â€œThroughout t he trial, IMP cannot be taken on [ADDRESS_1250835] LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 5 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 consecutive days and cannot be taken more than 3 days apart, regardless of dosing 
frequency,â€ was added . 
21. The text â€œ The investigator or designee must contact [CONTACT_893154]â€™s  
statusâ€ was removed from Sectio n 9.1 (Methods of Assigning Subjects to Treatment 
Groups ). 
22. Added the following text  reporting and recording of AEs to Section 10.1, â€œAEs occurring 
prior to the administration of IMP will only be reported if they are related to study 
procedures .â€ 
23. The text â€œâ€¦Screening Visit/V isit andâ€¦â€ was changed to â€œâ€¦Screening Visit/Visit 1 
andâ€¦â€ in Section 10.5. 
24. Definitions relating to  
 
 
 
was added.  
25. The exploratory endpoints  
 
26. Refined the definition of visits to the emergency department in Section 13.2 so that they 
are not considered SAEs in Mallinckrodt clinical studies.  
27. Clarified the collection times for AEs and SAEs will begin from the time of signing of 
the informed consent form through  the end -of-study/early termination visit in Section 
13.4. Also added the text,  â€œAll AEs and SAEs should be recorded in source documents; 
all AEs and SAEs that occ ur following the first dose of IMP should also be recorded in 
the eCRF. â€ 
28. Carbon dioxide and sodium were inadvertently removed from the listing of clinical 
laboratory tests in Attachment 1 ( Section 24.1). These analytes will be collected.  
29. Additional unspecified minor changes to punctuation, style, and formatting.  
 
 
PROTOCOL AMENDMENT [ADDRESS_1250836] 2017  
SUMMARY OF CHANGES  
 
Protocol Amendment 2 was developed primarily to add as a screening procedure. 
Additional revisions were made to clarify other specific protocol issues. The  protocol changes 
are summarized below:  
1. Section 2 (Contacts) was deleted. Remaining sections located after Section [ADDRESS_1250837] LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 6 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 2. Section 1.4  (Schedule of Study Events) and Section 6.1  (Inclusion Criteria) were revised 
to add as a screening procedure unless performed in the prior 3 years (new 
inclusio n criterion #5).  
3. Section 6.2  (Table 2 ) was revised to add a separate row for  with an extra â€˜Xâ€™ at the 
Screening Visit.  
4. Section 6 .1 (Inclusion Criteria) Inclusion criterion #4 was revised to remove the 
requirement for male contraception. Inclusion criterion #6 was revised to change  
 
5. Section 6 .1 (Inclusion Criteria - inclusion c riterion #9) and Section 7 .2 (Permitted During 
Study) were revised to delete â€œDRIâ€ since DRI drugs have not been shown to improve 
renal function.  
6. Section 6 .2 (Exclusion Criteria) - Exclusion crite rion #9 was revised to change 
â€œsenescenceâ€ to â€œsclerosisâ€. Exclusion criterion #24 (Table 11 -1, column 1) was revised 
to add "cyclophosphamide" to the 24 weeks before Screening Visit/Visit 1  column, since 
cyclophosphamide is used as a treatment for FSGS an d has a very long 
pharmacodynamic half -life. Exclusion criterion #27 was revised for better readability.  
7. Section 1 2.3.1 (Primary Efficacy Endpoint). Table 6  was revised,  
 
8. Section 13.4 was revised to clarify the reporting and recording of AEs.  
9. Corresponding appropriate changes were also made to Section 1.1  (Study Synopsis).  
10. Global edits were made to revise the number of study sites from [ADDRESS_1250838] other procedures and descriptions. The major protocol changes are 
summarized below:  
ï‚· Deleted â€œ(US and Canada only)â€ as the location of where  would 
be conducted.  
ï‚· Revised  the Emergency Contacts list to remove  as a backup medical 
monitor, and to add  as 
medical monitors.  
ï‚· Revised Inclusion Criteri on #5 to allow time from  
 
ï‚· Added Exclusion Criter ion #8: Subjects cannot have failed to achieve  
, as determined by [CONTACT_093], on more than 2  prior 
immunosupp ressive therapi[INVESTIGATOR_759279].  
ï‚· The following Secondary Endpoints were deleted or revised:  
ï€­  
  
 
 
 
  
 
  
 
  
 
  
 
 
  
 
 
 

Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 8 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï€­  
 
 
  
 
 
  
 
  
 
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
  
 
  
 
  
 
ï‚· The following Exploratory Endpoints were deleted or revised:  
 
 

Mallinckrodt ARD LLC  
MNK142 [ADDRESS_1250839] LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 11 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
   
 
  
 
  
 
  
 
  
 
  
 
 
  
 
 
  
 
 
  
 
 
ï‚· The following Secondary Efficacy Endpoints were added/revised:  
  
 
 
  
 
  
 
  
 
 
  
 
 

Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 12 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
   
 
 
ï‚· The following Secondary Safety Endpoint was added:  
ï€­ Summary of general safety profile, including adverse events (serious and non -
serious ), vital signs, and laboratory assessments by [CONTACT_893155].  
ï‚· The following Exploratory Endpoints were added/revised:  
  
 
 
  
 
 
  
 
 
  
 
  
  
  
 
  
 
 
  
 
 
  
   
  
 
  
 
  
 

Mallinckrodt ARD LLC  
MNK142 [ADDRESS_1250840]/Independent Ethics Committee  ................................ ......[ADDRESS_1250841] Description  ................................ ................................ ................................ ....36 
3.3. Dosage and Administration  ................................ ................................ ........................ 36 
3.4. Rationale  ................................ ................................ ................................ ..................... 36 
3.5. Risk/Benefit  ................................ ................................ ................................ ................ 37 
4. OBJECTIVES  ................................ ................................ ................................ ............. 37 
4.1. Primary Objecti ve ................................ ................................ ................................ .......37 
4.2. Secondary Objectives  ................................ ................................ ................................ .38 
4.3. Exploratory Objective(s)  ................................ ................................ ............................ [ADDRESS_1250842] S ................................ ................................ .................... 39 
6.1. Inclusion Criteria  ................................ ................................ ................................ ........ 39 
6.2. Exclusion Criteria  ................................ ................................ ................................ .......40 
6.3. Screen Failure  ................................ ................................ ................................ ............. 43 
7. PRIOR AND CONCOMITAN T MEDICATION  ................................ ...................... 44 
7.1. Prohibited Concomitant Medications  ................................ ................................ ......... 44 
7.2. Permitted During Study  ................................ ................................ .............................. 44 
8. PROCEDURES  ................................ ................................ ................................ .......... 44 
8.1. Screening Visit/Visit 1 (Study Days -63 to -3) Procedures  ................................ ........ 44 
8.2. Baseline Visit/Visit 2 Procedures  ................................ ................................ ............... 46 
8.3. Visit 3 Procedures (Week 4 Â± 5 Days)  ................................ ................................ .......46 
8.4. Visit 4 Procedures (Week 8 Â± 5 Days)  ................................ ................................ .......47 
8.5. Visit 5 Procedures (Week 12 Â± 5 Days)  ................................ ................................ .....47 
8.6. Visit 6 Procedures (Week 16 Â± 5 Days)  ................................ ................................ .....48 
8.7. Visit 7 Procedures (Week 20 Â± 5 Days)  ................................ ................................ .....48 
8.8. Visit 8 Procedures (Week 24 Â± 5 Days)  ................................ ................................ .....49 
8.9. Visit 9 Procedures (Week 26 + 5 Days)  ................................ ................................ .....49 
8.10.  Visit 10 Procedures (Week 30 Â± 5 Days)  ................................ ................................ ...50 
8.11.  Visit 11 Procedures (Week 34 Â± 5 Days)  ................................ ................................ ...50 
8.12.  Visit 12 Procedures (Week 38 Â± 5 Days)  ................................ ................................ ...51 
8.13.  Visit 13 Procedures (Week 42 Â± 5 Days)  ................................ ................................ ...51 
8.14.  Visit 14 Procedures (Week 46 Â± 5 Days)  ................................ ................................ ...52 
8.15.  Visit 15 Procedures (Week 50 Â± 5 Days)  ................................ ................................ ...52 
8.16.  End of Study/Early Termination Visit Procedures  ................................ ..................... [ADDRESS_1250843] Disposition and Exposure to IMP  ................................ ................................ ..64 
12.7.  Safety Analysis  ................................ ................................ ................................ ........... 64 
12.7.1.  Adverse Events  ................................ ................................ ................................ ........... 64 
12.7.2.  Clinical Laboratory Tests  ................................ ................................ ........................... 64 
12.7.3.  Physical Examination Findings  ................................ ................................ .................. 64 
12.7.4.  Vital Signs/Height and Weight  ................................ ................................ ................... [ADDRESS_1250844] INJURY  ................................ ................................ ................................ ....73 
20. RECORDS RE TENTION  ................................ ................................ .......................... 73 
21. BIOLOGICAL SAMPLES  ................................ ................................ ......................... 73 
22. PUBLICATION POLICY  ................................ ................................ .......................... 73 
22.1.  Spon sorâ€™s Publication Policy  ................................ ................................ ...................... 73 
22.2.  Investigatorâ€™s Ability to Publish  ................................ ................................ ................. [ADDRESS_1250845] LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 18 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 23. REFERENCES  ................................ ................................ ................................ ........... 74 
24. ATTACHMENTS  ................................ ................................ ................................ .......76 
24.1.  Attachment 1: Clinical Laboratory Tests  ................................ ................................ ....76 
24.2.  Attachment 2: Evaluation of Edema  ................................ ................................ ........... 77 
24.3.  Attachment 3: Secondary Causes of FSGS  ................................ ................................ [ADDRESS_1250846] OF TABLES  
Table  1: Schedule of Study Events  ................................ ................................ ........................... 30 
Table  2: Prohibited Medications Relative to Screening Visit/Visit 1  ................................ .......42 
Table  3: Prohibited Medications Relative to Baseline Visit/Visit 2  ................................ ......... 42 
Table  4: Timing of Baseline Visit/Visit 2 Relative to FSGS Treatment at Screening  ............. 45 
Table  5: IMP Treatment Schedule  ................................ ................................ ............................ 55 
Table  6: 62 
Table  7: Adverse Event Relationships  ................................ ................................ ...................... 66 
Table  8: Adverse Event Severity Grades  ................................ ................................ .................. 67 
Table  9: Reporting Requirements for Adverse Events  ................................ ............................. [ADDRESS_1250847] OF FIGURES  
Figure  1: Study Overview  ................................ ................................ ................................ .......... [ADDRESS_1250848] LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 20 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 DISCLOSURE STATEMENT  
Restricted Distribution of Documents  
This document contains information that is confidential and proprietary to the sponsor. This 
information is being provided to the investigator solely for the purpose of evaluating and/or 
conducting a clinical study for the sponsor. The investigator may disclose the contents of this 
document only to study personnel under his/her supervision, institutio nal review boards 
(IRBs)/independent ethics committees (IECs), or duly authorized representatives of regulatory 
agencies for this purpose under the condition that they maintain confidentiality. The contents of 
this document may not be used in any other cli nical study, disclosed to any other person or 
entity, or published without the prior written permission of the sponsor. The foregoing shall not 
apply to disclosure required by [CONTACT_17140]; however, the investigator will give prompt 
notice to the sponso r of any such disclosure. All other nonpublic information provided by [CONTACT_103], as well as any information that may be added to this document, also is confidential and 
proprietary to the sponsor and must be kept in confidence in the same manner as the c ontents of 
this document.  
  
Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 21 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 SPONSOR SIGNATURE  
[CONTACT_155622], in conjunction with the signature [CONTACT_6823], confirms the agreement of 
both parties that the clinical study will be conducted in accordance with the protocol and 
applicable laws and other regulations including, but not limited to, the International Co uncil for   
Harmonisation (ICH) Guideline for Good Clinical Practice (GCP), the US Code of Federal 
Regulations (CFR) (where applicable), all applicable national and local regulations, prot ections 
for privacy, and generally accepted ethical principles for human research such as the Declaration 
of Helsinki.  
Nothing in this document is intended to limit the authority of a physician to provide emergency 
medical care.  
 
 
Sponsor Signature   [CONTACT_1782] o f Signature  
(DD Month YYYY)  
 
   
Sponsor Name (print)    
  
@mallinckrodt.comDigitally signed by @mallinckrodt.com 
DN: cn @mallinckrodt.com 
Reason: I am approving this document 
Date: 2019.06.03 16:44:32 -04'00'

Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 22 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 INVESTIGATOR SIGNATU RE  
My signature [CONTACT_155625], but not limited to, the International Council 
for Harmonisation  (ICH) Guideline for Good Clinical Practice (GCP), the US Code of Federal 
Regulations (CFR) (where appropriate), all applicable national and local regulations, protections 
for privacy, and generally accepted ethical principles such as the Declaration of Helsinki.  
Nothing in this document is intended  to limit the authority of a physician to provide emergency 
medical care.  
 
 
 
Investigatorâ€™s Signature   [CONTACT_1217]  
(DD Month YYYY)  
 
   
Investigatorâ€™s Name [CONTACT_13693] (print)    
 
  
Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 23 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ABBREVIATIONS  
Abbreviation  Term 
2x/week  Twice a week  
3x/week  Three times a week  
ACEi  Angiotensin -converting enzyme inhibitor  
ACTH  Adrenocorticotropic hormone  
AE Adverse event  
ALT  Alanine  aminotransferase  
ANC  Absolute  neutrophil  count 
ARB  Angiotensin  receptor  blocker  
AST  Aspartate  aminotransferase  
BMI  Body mass index  
CFR  Code of Federal Regulations  
CNI Calcineurin inhibitor  
CR Complete remission  
eCRF  Electronic case report form  
eGFR  Estimated glomerular  filtra tion rate 
ESRD  End stage  renal  disease  
FDA  Food and Drug Administration  
FSGS  Focal segmental glomerulosclerosis  
GCP  Good Clinical Practices  
HbA1c Glycosylated hemoglobin  
HBsAg  Hepatitis B surface antigen  
HBcAb  Hepatitis B core antibody  
Mallinckrodt ARD LLC  
MNK142 [ADDRESS_1250849]  
ITT Intent -to-treat 
IXRS  Interactive  Phone/Web  Response  System  
KDIGO  Kidney Disease Improving Global Outcomes  
LDL  Low density  lipoprotein  
MCR  Melanocortin  receptor  
MDRD  Modification  of Diet in Renal  Disease  
MMF  Mycophenolate mofetil  
PR Partial remission  
SAE  Serious adverse event  
SC Subcutaneous  
SF-36 Short Form (36) Health Survey  
TB Tuberculosis  
Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 25 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Abbreviation  Term 
TEAE  Treatment -emergent adverse event  
U Unit( s) 
US [LOCATION_002]  
ULN  Upper  limit of normal 
uPCR  Urine protein creatinine ratio  
  
Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 26 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 1. PROTOCOL SUMMARY  
1.1. SYNOPSIS  
Study Title: Treatment of Proteinuria Due to T reatment Resistant or Treatment I ntolerant Idiopathic 
Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)  
Protocol Number:  MNK14224049  Type: Phase 4 (US)/Phase 2 (all other countries)  
Condition/Disease: Idiopathic focal segmental glomerulosclerosis (FSGS)  
Approximate Number of Subjects:  [ADDRESS_1250850] Participation:  Up to 65 weeks  
Approximate Number of Study 
Centers:  100 globally  Approximate Duration of Study:  5 years  
Design: 
This is a multicenter, multiple dose study to examine the effect of Acthar (repository corticotropin injection, 
hereafter referred to as Acthar) in adult subjects with idiopathic f ocal segmental glomerulosclerosis (FSGS) who 
have failed to achieve remission with, or who are intolerant of, 1 or more previous immunosuppressive therapi[INVESTIGATOR_014]. 
All enrolled subjects will be treated in an unblinded fashion with Acthar 1 mL (80 U) subcutaneous ly (SC) 
3 times per week (3x/week) for 50 weeks to assess the safety and tolerability of Acthar. Taper to 1 mL SC  twice a 
week (2x/week) for tolerability reasons will be allowed. All subjects will have an End of Study/Early 
Termination Visit [ADDRESS_1250851] ( IMP). 
Objectives and Endpoints:  
Primary Objective  Primary Endpoints  
To confirm the safety and tolerability of 
Acthar in the induction of remission of 
proteinuria in subjects with primary FSGS 
who are res istant to, or intolerant of, at 
least 1 prior immunosuppressive therapy  ï‚· Severity and frequency of adverse events ( AEs) 
ï‚· Changes in physical findings  
ï‚· Changes in clinical laboratory findings  
ï‚· Changes in vital signs  
 
Secondary Objective  Secondary Endpoint  
None None 
Exploratory Objective  Exploratory Endpoints  
ï‚· To demonstrate  
 
 
 
 ï‚·  
 
  
  
  
 
  
 
  
 

Mallinckrodt ARD LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 27 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Study Title: Treatment of Proteinuria Due to T reatment Resistant or Treatment I ntolerant Idiopathic 
Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)  
Protocol Number:  MNK14224049  Type: Phase 4 (US)/Phase 2 (all other countries)  
Condition/Disease: Idiopathic focal segmental glomerulosclerosis (FSGS)  
ï‚·  
  
  
 
  
  
  
  
  
 
  
 
  
  
 
Entry Criteria:  
Male or nonpregnant, nonlactating female subjects 18 years of age or older with primary FSGS (confirmed by 
[CONTACT_530215]) who are nephrotic (uPCR ï€¾ 3.0 mg/mg and estimated glomerular filtration rate [eGFR] at 
least 30 mL/min/1.73 m2) and who have failed to achieve sustained CR or PR of proteinuria with at least [ADDRESS_1250852] be treated with an angiotensin converting enzyme inhibitor or angiotensin receptor blocker 
(or have documentation of intolerance), for at least 4 weeks prior to Screening Visit/Visit 1 with blood pressure 
no m ore than 150/90. Subjects also must be negative for hepatitis B, hepatitis C, have no history of tuberculosis 
(TB) or other contraindication as per the [LOCATION_002] (US) Prescribing Information for Acthar, have no history 
of Type [ADDRESS_1250853] taken 
Rituximab or cyclophosphamide 24 weeks prior to Screening Visit/Visit 1, any investigational treatments for 
FSGS or oral corticosteroids (unless used to treat FSGS) for 12 weeks  prior to Screening Visit/Visit 1, any 
intravenous/intramuscular corticosteroids (unless used to treat FSGS) for 8 weeks prior to Screening Visit/Visit 1, 
or have been involved in a therapeutic drug/device trial (other than for FSGS) 4 weeks prior to Scree ning 
Visit/Visit 1.  
Concomitant Medications and Treatments:  
A stable dose of angiotensin -converting enzyme inhibitor/ angiotensin receptor blocker is required throughout 
study participation. Subjects requiring other antihypertensive medications must be on  a stable dose at least [ADDRESS_1250854] dose of Acthar.  
Subjects are not permitted to take any enteral or parenteral corticosteroid, live or live -attenuated vaccine or 
systemic immunosuppressive medication during the study.  
All medications and n ondrug therapi[INVESTIGATOR_014] (eg, blood transfusions, oxygen supplementation) at Screening Visit/Visit 
[ADDRESS_1250855] LLC  
MNK142 2  
Protocol MNK14224049 Amendment 3                                                                              Page 28 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Study Title: Treatment of Proteinuria Due to T reatment Resistant or Treatment I ntolerant Idiopathic 
Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)  
Protocol Number:  MNK14224049  Type: Phase 4 (US)/Phase 2 (all other countries)  
Condition/Disease: Idiopathic focal segmental glomerulosclerosis (FSGS)  
Investigational Medicinal Product and Treatment Administration:  
Acthar 1 mL (80 U) SC 3x/week will be administered to a ll subjects from Week 0 to 50. Tapering of dose to 
1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 
2x/week it must remain at this level. Subjects unable to tolerate 1 mL SC 2x/week will be discontinu ed. 
Efficacy Evaluations : 
There are no efficacy assessments.  
Safety Evaluations:  
The following safety assessments will be evaluated: adverse events, physical examinatio ns, clinical laboratory 
tests, vital signs , medical and surgical history, height and height .  
Exploratory Evaluations:  
The following exploratory assessments will be evaluated:  
 
 
Statistical Methods:  
Analysis Populations:  
Intent -to-Treat (ITT) Population: All enrolled subjects who receive 1 or more doses of IMP and who contribute 
any exploratory data to the study.  
Per-Protocol Population: the subset of the ITT popu lation who complete the study as per protocol. Completer 
populations will be further defined in the statistical analysis plan.  
Safety Population: all enrolled subjects who receive 1 or more doses of IMP.  
Sample Size:  
Approximately 60 subjects will be enrolled. Formal sample size calculations were not performed.  
Assessments:  
Efficacy: There are no efficacy endpoints.  
Safety: The following safety assessments will be evaluated:  adverse events, physical examinatio ns, clinical 
laboratory tests, vital signs , medical and surgical history, height and height .  
Exploratory: Exploratory endpoints will be summaries with descriptive statistics only.  
 
  
 

Mallinckrodt ARD LLC  
MNK1422  
Protocol 14224049 Amendment 3                                                                                                                                                          Page 29 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 1.2. STUDY SCHEMATIC AND SCHEDULE OF EVENTS  
1.3. Study Schematic  
Figure 1: Study Overview  
 
 
 
 
 
 
 
 
 
 
 
 
 Screening  
    Open Label /Open -label Extension  Acthar 1 mL (80 U) 
SC 3x/w  
   Follow -up Period  
Day -63 â€“ Day -3  Weeks 53 -56 
Taper to Acthar 1 mL (80U) SC 2x/w 
permitted for safety  
Weeks 51 â€“ 54  Weeks 0 â€“ 50  Weeks 51 â€“ 52  Taper  
to 2x/w  
   
Follow -up 
Period  
Mallinckrodt ARD LLC  
MNK1422  
Protocol 14224049 Amendment 3                                                                                                                                                          Page 30 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 1.4. Schedule of Study Events  
Table 1: Schedule of Study Events  
Period Screening  
(Day -63 
to -3) Baseline Open Label/Open -label Extension  
 
Taper Safety Visita 
End of Study/Early 
Terminationb 
VISIT #: Visit window is Â± 5 days 
starting with Visit 2 (except at 
V9 where window is + 5 days 
only) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Week  0 4 8 12 16 20 24 26 30 34 38 42 46 50  54 or 
56 
Informed consentc X                 
Inclusion/exclusion criteria review  X X                
Demographics  X                 
Medical/surgical history  X                 
Current medical condition review  X X X X X X X X X X X X X X X X X 
Complete physical examination  X                X 
Limited physical examination   X X X X X X X X X X X X X X X  
Vital signs  X X X X X X X X X X X X X X X X X 
Height (screening only) and weight  X X X X X X X X X X X X X X X X X 
Clinical laboratory tests (serum 
chemistry and CBC w/diff)  X X X X X X X X  X X X X X X Xd X 
HbA1c  X    X   X    X   X   
Nonfasting lipid panel   X   X   X    X   X   
  X  X  X  X   X  X  X   
 X X  X  X  X   X  X  X   

Mallinckrodt ARD LLC  
MNK1422  
Protocol 14224049 Amendment 3                                                                                                                                                          Page 31 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Period Screening  
(Day -63 
to -3) Baseline Open Label/Open -label Extension  
 
Taper Safety Visita 
End of Study/Early 
Terminationb 
VISIT #: Visit window is Â± 5 days 
starting with Visit 2 (except at 
V9 where window is + 5 days 
only) [ADDRESS_1250856] LLC  
MNK1422  
Protocol 14224049 Amendment 3                                                                                                                                                          Page 32 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Period Screening  
(Day -63 
to -3) Baseline Open Label/Open -label Extension  
 
Taper Safety Visita 
End of Study/Early 
Terminationb 
VISIT #: Visit window is Â± 5 days 
starting with Visit 2 (except at 
V9 where window is + 5 days 
only) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Week  0 4 8 12 16 20 24 26 30 34 38 42 46 50  54 or 
56 
 
  X      X       X   
Concomitant medications/adverse 
events  ----------------------------------------------------------- X-------------------------------------------------------------------------  
aIf IMP is tapered from 3x/week to 2x/week for safety and/or tolerability issues, a Taper Safety Visit will be conducted 2 weeks later (See  Section 8 .17).  
bSubjects receiving 2x/week dosing (tapered for safety) will return at Week 54 + 5 days and subjects dosing 3x/week will retur n at Week 56 + 5 days.  
cSubjects (US only) with stored  will be reconsented after implementation of Amendment 3 to allow for sponsor/site contact [CONTACT_893156] a dditional sample 
examination.  
dClinical laboratory tests will be done if the reason for discontinuation was related to laboratory t est results.  
eR   
fFor subjects requiring IMP taper only.  
gSubject or subjectâ€™s caregiver will administer the first dose of IMP in the clinic under the supervision of the study sta ff. The subject will be observed in the clinic for at least [ADDRESS_1250857]/Independent Ethics Committee  
It is the responsibility of the investigator to obtain the approval of the IRB/  IEC before the start 
of the study. The investigator will provide Mallinckrodt with a statement of compliance from the 
IRB/IEC and/or the US Department of Health and Human Services general assurance number. A 
copy of the approval letter along with a roster of IRB/IEC members and compliance letter and/or 
the US Department of Health and Human Services general assurance number will be retained as 
part of the study records. During the course of the study, the investigator will provide timely and 
accurate reports to the IRB/IEC on the progress of the study at appropriate intervals (not to 
exceed 1 year) and at the completion of the study. The investigator will notify the IRB/IEC of 
SAEs or other significant safety findings per IRB/IEC guidelines. The study protocol, informed 
consent form (ICF), advertisements ( if any), and amendments (if any) will be approved by [CONTACT_5040]/IEC in conformance with international, national and local regulatory requirements; and the 
Code of Federal Regulations (CFR) , Title  21, Part 56 (where applicable).  
2.2. Ethical Conduct of the Study  
The study will be conducted in full compliance with applicable international, national and local 
regulatory requirements; [LOCATION_002] (US) Food and Drug Administration (FDA) regulations 
including 21 CFR 314.106 and 312.120,  (where applicable); and ICH guid elines for GCP and in 
accordance with the ethical principles that have their origins in the Declaration of Helsinki.  
2.3. Subject Information and Consent  
The ICF must be approved by [CONTACT_135785]/IEC before any subject provides consent. 
The investigat or will provide Mallinckrodt with a copy of the IRB/IEC -approved ICF and a copy 
of the IRB/IECâ€™s written approval before the start of the study.  
At the Screening Visit/Visit 1, subjects will read the ICF and a Health Insurance Portability and 
Accountabilit y Act (HIPAA) authorization form (if applicable) after being given an explanation 
of the study. Before signing the ICF and the HIPAA authorization form (if applicable), subjects 
will have an opportunity to discuss the contents of these forms with study sit e personnel.  
Subjects must assent understanding of and voluntarily sign these forms in compliance with ICH 
GCP guidelines and 21  CFR, Parts 50 and 312 (where applicable), before participating in any 
study -related procedures. Subjects will be made aware th at they may withdraw from the study at 
any time. Subjects unable to give written informed consent must orally assent to the procedures, 
and written informed consent must be obtained from a legally authorized representative in 
accordance with national and l ocal laws, as applicable.  
The ICF must contain all applicable elements of informed consent and the mandatory statements 
as defined in by [CONTACT_410492]. All versions of each 
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250858]'s signed ICF must be kept on file by [CONTACT_893157]/or authorized Mallinckrodt personnel. Signed copi[INVESTIGATOR_893137], if applicable, will be given to the subject.  
The subjects will be made aware of their right to see and copy their records related to the study 
for as long as the investigator has possession of this information. If the subject withdraws 
consent and/or HIPAA authorization, the investigator can no longer disclose health information, 
unless it is needed to preserve the scientific integrity of the study.  
3. BACKGROUND INFORMATI ON AND RATIONALE  
3.1. Overview  
Focal  segmental  glomerulosclerosis (FSGS) is a pattern of histologic renal injury marked by 
[CONTACT_893158] (idiopathic) or 
secondar y. The renal injury results from insults directed at or within the podocyte that eventually 
lead to a rearrangement of the actin cytos keleton and effacement of foot processes in the 
glomerular basement membrane.  The histologic lesions differ in their location relative to the 
glomerular vascular and tubular poles and in the morpho logic features of hyalinosis, capi[INVESTIGATOR_893138], and hype rcellularity (Dâ€™Agati et al, 2011 ).  
Primary, or idiopathic,  FSGS is defined by [CONTACT_893159]. 
The glomerulosc lerosis of secondary FSGS usually results from an adap tive respon se to scarring 
from  a previous injury or direct toxic injury to the podocytes. Second ary FSGS may be associated 
with viral infections, be drug induced, or result from cond itions marked by [CONTACT_893160][INVESTIGATOR_893139]. It is important to distinguish primary from 
seconda ry FSGS as the latter is treated only with renin angiotensin system blockade and not 
immunosupp ressive therapy. In addition to clinical history and laboratory findings such as 
hypoalbuminemia and hyperlipi[INVESTIGATOR_035], histological findings may help differentiate primary from 
secondary  FSGS, with the former exhibiting more widespread  foot process effacement under 
electron microscopy (Dâ€™Agati et al, 2011 ). 
Eighty percent  of cases of FSGS are primary and t he incidence of primary FSGS has dramatically 
increased over the past 20 to 30 years (Dâ€™Agati et al, 2011 ). Primary FSGS is usually a progressive 
disorder with a low likelihood of spontaneous remission.  Approximately 50% of patients will reach 
end stage renal disease (ESR D) over a period of 5 to 8 years from the time of biopsy if either 
unresponsive to treatment or not treated (Korbet, 1999 ). Five to [ADDRESS_1250859] FSGS as their primary cause  of renal failure 
(Malaga -Diequez et al, 2015 ). The prognosis of patients with primary FSGS is best predicted by 
[CONTACT_893161]. Patients who undergo a complete remission 
(CR)  or partial remission (PR)  have a much better chance of renal survival, 80% or greater  over a 
10-year period, than those who are  unresponsive (Troyanov et al, 2005 ). 
The goal of therapy is to induce  CR of proteinuria that in turn leads to the preservation of renal 
function. The achievement of PR or even substantial reductions in proteinuria translates into less 
rapid loss of renal function. Adult patients with primary FSGS who have nephrotic range 
proteinuria are usually treated with renin angiotensin system blockade and immunosuppres sive 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250860] nephrotic range  proteinuria 
(Kitiyakara et al, 2003 ). The initial Kidney  Disease Improving Global Outcomes (KDIGO) 
recommended  immunosuppres sive therapy for most adults with primary FSGS is oral prednisone,  
with calcineurin inhibitors (CNI) reserved for those at high risk for glucoc orticoid-induc ed 
toxicity. There is no universal agreement on the dose and duration of prednisone therapy, though 
the current KDIGO Clinical Practice Guid elines for glomeruloneph ritis recommends treatment 
with high doses  of prednisone,  1 mg/kg/day or 2 mg/kg every other  day, for between [ADDRESS_1250861] 12 months.  A combinat ion of 
mycophenol ate mofetil (MMF)  and high dose dexamethasone is the KDIGO recommended 
alternative for patients who do not tolerate or respond to the CNI, although MMF is also not FDA -
approved for this indication  (KDIGO Work Group, 2012 ). 
About 50%  of patients with primary FSGS will be resistant to therapy with corticosteroids 
(Bose  and Cattran, 2014 ). The prolonged duration of high doses of prednisone is frequently 
associated with significant side effects  including  the development or worsening of diabetes, 
weight gain, fluid retention, osteoporosis, behavioral changes, and infection. Between 30% and 
40% of patients resistant to steroids will also be resistant to CNIs, and in those who respond, 
relapse is common (Cattran et al, 2007 ). CNIs are also associated with significant side effects, 
such as hypertension and glucose  intolerance, and the long-term neph rotoxicity associated with 
their use may poten tially abrogate the benefit from the reduction in proteinuria. These side effects 
make a number of patients with FSGS intolerant to the therapi[INVESTIGATOR_014]. Thus a significant unmet need 
for efficacious therapi[INVESTIGATOR_893140].  
As described in the Package Insert, H.P. ActharÂ® Gel (repository corticotropin injection, 
hereafter referred to as Acthar)  is a highly purified porcine ad renocorticotropic hormone (ACTH) 
analogue ( Mallinckrodt ARD  LLC, 2015 ). Acthar is a purified sterile preparation of the ACTH 
formulated in 16%  gelatin to provide a prolonged release after intramuscular or subcutaneous 
injection. ACTH is a member of the family of structurally related peptides known as melanoco rtin 
peptides. Melanocortin peptides, which in addition to ACTH include the Î±-, Î²-, and Î³-melanoc yte 
stimulating hormones,  are derived from the natural protein pro-opi[INVESTIGATOR_893141]. They bind to 
cell surface G-prote in coupled receptors known as melanoco rtin receptors (MCR s). Five subtypes 
of MCRs have been  identified to date (MC1 R-MC5 R), each with different tissue distributions, 
binding affinity characteristics, and physiological roles (Getting, 2006 ). ACTH is a known agonist 
for all 5 subtypes of MCR (Schioth et al, 1995 ) and recent experiments demonstrate that Acthar 
also has agonist activity for all 5 MCRs (Wright, 2018 ). 
The kidney is a major target of the melanocortin hormone system. MCRs have been expressed 
throughout the kidney, including on glomerular  podoc ytes, and receptor activations initiate 
downstream signaling cascades that ultimately lead to amelioration of renal injury (Gong and 
Dworkin, 2010 ). Agonists of the MC1R  receptor were shown to reduce oxidative stress and 
improve glomerular morpholo gy in nephr otic rats with passive Heymann nephr itis (Lindskog et 
al, 2010 ). Acthar has been shown to diminish podocyte injury and apopt osis and reduce foot 
process effacement in a rodent subtotal nephrectomy model,  an animal model of FSGS (Gong  and 
Dworkin, 2010 ). In addition to improved podoc yte structure and function, glomerulosclerosis, 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250862] 
of ACTH (including Acthar) on  proteinuria. In an observational study, 1 patient with FSGS and 
nephrotic range proteinuria who was resistant  to steroid and cytotoxic therapy was treated with 
synthe tic ACTH and attained PR (Berg and Arnadottir, 2004 ). A published case report 
documented the development of PR in a young woman with FSGS and massive proteinuria 
(greater than  10 grams) who was treated with Acthar  (80 units [ U] subcutaneously [SC] twice 
weekly for 6 months)  after having failed to respond to corticosteroids, mycophenol ate and a CNI 
(Bomback et al, 2011 ). In a prosp ective open  label study, [ADDRESS_1250863] 
2 previous therapi[INVESTIGATOR_893142] 80 U  SC twice a week  for 6 months and 1 patient 
attained CR ( Bomback et al, 2012 ).  
The largest experience of treating primary FSGS with Acthar is in [ADDRESS_1250864] one course of 
corticosteroids. Patients had received a mean of 2.2 Â± 1.[ADDRESS_1250865] to follow up after 5 weeks  of Acthar . 
Seven of the 24 patients had remission of proteinuria, 5 with PR and 2 with CR and 5 of  the 7 
patients had sustained remission with a median follow up time of 90 weeks (Hogan et al, 2013 ).  
3.2. Product Description  
Acthar is currently approved in the US for inducing a diuresis or remission of proteinuria in the 
nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus 
(Mallinckrodt ARD  LLC, 2015 ). Acthar is a proprietary ACTH mixture isolated from porcine 
pi[INVESTIGATOR_893143].  
3.3. Dosage and Administration  
Investigational medicinal product (IMP) will be used to denote active drug (Acthar) and/or 
matching placebo.  
In this study all subjects will receive open lab el treatment with Acthar 1 mL (80 U)  SC 3 times 
per week (3x/week) for 50 weeks. Taper to 1 mL SC  twice a week (2x/week) for safety and/or 
tolerability reasons will be allowed. If the dose is tapered to 1 mL SC 2x/week it must remain at 
this level for the remainder of the study. Subjects unable to tolerate 1 mL SC 2x/week will be 
discontinued.  
3.4. Rationale  
The doses for this study were chosen based on safety and feasibility data. The prescribing 
information for Acthar recommends the use of 40 to 80 U administe red intramuscularly or SC 
every 24 to 72 hours in adults and children over 2 years of age; the specific dose is 
individualized according to the medical condition ( Mallinckrodt ARD  LLC , 2015 ). The maximal 
dose is 80 to 120 U SC daily, which has been used safely for the treatment of acute multiple 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 37 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 sclerosis exacerbations over a period of 2 to 3 weeks. Recently published data suggests that 
based on serum cortisol -equivalent exposure (assuming linearity), 80 U of Acthar equates to  
30 mg of intravenous methylprednisolone ( Lal et al, 2015 ).  
Higher doses of Acthar and longer periods of exposure are well tolerated and associated with 
improved outcomes in patients with idiopathic nephrotic syndrome. In the largest published 
experience of Acthar in FSGS, patients received treatment for [ADDRESS_1250866] 
profile was considered acceptable ( Hogan et al, 2013 ). A case report of 10 patients with 
treatment resistant FSGS documented  that prolonged therapy with synthetic ACTH for a median 
of 18 months was well tolerated ( Berg et al, 2012 ). In a study of patients with membranous 
nephropathy, another cause of idiopathic nephrotic syndrome, higher exposure to  Acthar was 
well tolerated and associated with higher rates of remission of proteinuria ( Hladunewich et al, 
2014 ). 
3.5. Risk/Benefit  
Known potential risks of Acthar include potential Cushingâ€™s Syndrome, hypertension, 
gastrointesti nal perforation and bleeding, behavioral and mood disturbances, hyperglycemia, 
enhanced risk for infection, decrease in bone density and/or worsening of peripheral edema 
(Mallinckrodt ARD  LLC , 2015 ). 
Primary FSGS is a progressi ve disorder associated with a low likelihood of spontaneous 
remission and high risk of reaching ESRD if not treated or unresponsive to treatment. The 
incidence of primary FSGS is increasing, as is the number of patients reaching ESRD because of 
the disorde r. Current therapi[INVESTIGATOR_893144] a large number of patients and are associated 
with significant side effects that limit their use and potentially abrogate their benefit. Evidence 
suggests that Acthar will be beneficial in reducing proteinuria and the subsequent deterioration in 
renal function in patients who are resistant or intolerant to currently recommended treatments.  
4. OBJECTIVES  
4.1. Primary Objective  
 
Primary Objective  Primary Endpoints  
To confirm the safety and tolerability of 
Acthar in the induction of remission of 
proteinuria in subjects with primary FSGS 
who are resistant to, or intolerant of, at 
least 1 prior immunosuppressive therapy  ï‚· Severity and frequency of adverse events (AEs)  
ï‚· Changes in physical findings  
ï‚· Changes in clinical laborator y findings  
ï‚· Changes in vital signs  
 
 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 38 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 4.2. Secondary Objectives  
There are no secondary objectives  or endpoints . 
4.3. Exploratory Objective(s)  
 
Primary Objective  Primary Endpoints  
Exploratory Objectives  Exploratory Endpoints  
ï‚· To demonstrate  
 
 
 
 ï‚·  
 
  
  
  
 
  
 
  
 
  
  
  
 
  
  
  
  
  
 
  
 
  
  
 
 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250867] failed to achieve remission w ith, or who are intolerant of, one  or more previous 
immunosuppressive therapi[INVESTIGATOR_014]. Approximately 60 subjects will be enrolled . 
All enrolled subjects will be treated with Acthar 1 mL (80 U) SC 3x/week for  50 weeks . Taper to 
1 mL SC  2x/week for safety and/or tolerability reasons will be allowed. If the dose is tapered to 
1 mL SC 2x/week it must remain at this level for the remaind er of the study. Subjects unable to 
tolerate 1 mL SC 2x/week will be discontinued.   
All subjects will participate in the Follow -up Period at the conclusion of their participation in the 
study (including those who terminate early). The Follow -up Period will  be [ADDRESS_1250868] (IMP) . 
For subjects receiving IMP 3x/week, the dose of IMP will be tapered to 2x/week for 2 weeks and 
then discontinued. For subjects receiving IMP 2x/week  (tapered fr om 3x/week to 2x/week for 
safety) , the IMP will be discontinued without a taper. All subjects , including those who terminate 
early,  will then have an End of Study/Early Termination Visit [ADDRESS_1250869] dose of 
IMP.  
5.2. Approximate Duration of Subjec t Participation  
Subjects will participate in the study for a total of approximately 65 weeks, including a 
Screening Visit/Visit [ADDRESS_1250870] meet all of the following criteria for inclusion in the study at the Screening 
Visit/Visit 1 and the Baseline Visit/Visit 2 : 
1. Must be adequately informed and understand the nature and risks of the study and must 
be able to provide a signature [CONTACT_477587].  
2. Must be â‰¥ 18 years of age at Screening Visit/Visit [ADDRESS_1250871] be of nonchildbearing potential (hi story of hysterectomy, bilateral 
oophorectomy, or are postmenopaus al with no history of menstrual  flow in the 12 months 
prior to Screening Visit/Visit  1), or if of childbearing potential must be nonpregnant, 
nonlactating and agree to use effective contraception with a male partner throughout 
study participation and for 4 weeks after ending study participation. Acceptable forms of 
contraception include hormo nal measures (oral contraceptive pi[INVESTIGATOR_3353], contraceptive patch, 
contraceptive ring, injections), intrauterine devices, double barrier method (condom plus 
diaphragm, condom or diaphragm plus spermicidal gel or foam), and abstinence.  
4. Must have a history of pri mary FSGS confirmed by a renal biopsy . 
5. Must be willing to undergo a renal biopsy unless the most recent renal biopsy â‰¤ 3 years 
of the Screening Visit/Visit 1.  
6. Must have a t otal urine protein creatinine ratio (uPCR)  ï€¾ 3.0 mg/mg  at Screening 
Visit/ Visit 1. 
7. Must have an esti mated glomerular filtration rate (eGFR) â‰¥ 30 mL/min/1.73 m2 at the 
Screening Visit/Visit 1  as calculated by [CONTACT_941] 4 -variable modification of diet in renal 
disease (MDRD) study equation.  
8. Must have failed  to achieve sustained CR or PR of proteinuria as determined by [CONTACT_294855] â‰¥ [ADDRESS_1250872] int olerance to â‰¥ [ADDRESS_1250873] been treated with an an giotensin converting enzyme inhibitor (ACEi) or 
angiotensin receptor blocker (ARB) for â‰¥ 4 weeks prior to Screening Visit/Visit  1 and on 
stable maintenance dose(s) for â‰¥14 days prior to Screening Visit/Visit  [ADDRESS_1250874] a documented intolerance to 
ACEi or ARB with approval from the MM prior to enrollment. Subjects taking other 
antihypertensive medication(s), must be on a stable dose of for â‰¥ 4 weeks prior to the 
Screening Visit/Visit 1.  
10. Must have a mean s ystolic blo od pressure â‰¤ 150 mm Hg and a diastolic blo od pressure  of 
â‰¤ 90 mm Hg determined by [CONTACT_144372] â‰¥ [ADDRESS_1250875] 5 minutes 
apart at Screening  Visit/Visit  1 and at the Baseline Visit/Visit 2.  
11. Must be able to communicate effectively with study personnel.  
12. Must be able and willing to follow all protocol requirements and study restrictions.  
13. Must be able and willing to return for all study visits.  
6.2. Exclusion Criteria  
Subjects are ineligible for study participation if they meet any of the following criteria at the 
Screening Visit/Visit 1 or Baseline Visit/Visit 2 : 
1. Is from a vulnerable population, as defined by [CONTACT_477560] 45, Part 46, Section 
46.111(b) and other local and national regulations, including but not limited to, 
employees (temporary, part -time, full time, etc) or a family  member of the research staff 
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 41 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 conducting the study, or of the sponsor, or of the clinical research organization, or of the 
IRB/IEC.  
2. Is unwilling to receive, or is intolerant of, subcutaneous injections.  
3. Has any history of use of ACTH preparations for treat ment of nephrotic syndrome 
(including but not limited to Acthar and SynacthenÂ®). 
4. Has a history of sensitivity to ACTH preparations (including but not limited to Acthar 
and Synacthen).  
5. Has a history of sensitivity to porcine protein products.  
6. Has a body mas s index (BMI) ï€¾45 kg/m2 at Screening Visit/Visit 1.  
7. Has secondary FSGS, including but not limited to, obesity, known genetic cause, reduced 
kidney mass, Human Immunodeficiency Virus (HIV), intravenous heroin abuse, or sickle 
cell anemia (a full list of sec ondary causes of FSGS is included in Section 24.3). 
8. Cannot have failed to achieve sustained CR or PR of  proteinuria, as determined by [CONTACT_1275], on more than 2  prior immunosuppressive therapi[INVESTIGATOR_893145].  
9. Has had a renal biopsy demonstrating ï€¾ 50% global glomerular sclerosis , or ï€¾ 50% 
cortical interstitial fibrosis, or collapsing FSGS.  
10. Has any known contraindication(s) to Acthar ( Mallinckrodt ARD  LLC, 2015 ) including, 
but not limited to:  
ï€­ Any known history of scleroderma, osteoporosis, or ocular herpes s implex.  
ï€­ Any current uncontrolled hypertension, primary adrenocortical insufficiency, or 
adrenal cortical hyperfunction.  
ï€­ Any current congestive heart failure (defined as [LOCATION_001] Heart Association 
Functional Class III to IV).  
ï€­ Peptic ulcer (within 6 months p rior to Screening Visit/Visit 1).  
ï€­ Recent major surgery (within 6 months prior to Screening Visit/Visit 1, renal 
biopsy is not considered an exclusionary surgical procedure).  
11. Has a history of chronic active hepatitis; acute  or chronic hepatitis B; or acute or chronic 
hepatitis C.  
12. Has a history of tuberculo /sis (TB) infection, any signs/symptoms of TB, or any close 
contact [CONTACT_893162].  
13. Has a clinically significant infection requiring intravenous administration of antibiotics  
and hospi[INVESTIGATOR_61342] 4 weeks prior to Screening Visit/Visit 1.  
14. Has known immune compromised status, including but not limited to, individuals who 
have undergone organ transplantation or who are known to be positive HIV.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 42 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 15. Has Type 1 or Type 2 diabetes  mellitus (prior diagnosis of gestational diabetes mellitus is 
not exclusionary).  
16. Has had any of the following in the 12 weeks prior to Screening Visit 1/Visit 1: unstable 
angina confirmed by a cardiologist, myocardial infarction, coronary artery by[CONTACT_112906], 
percutaneous trans -luminal coronary angioplasty, transient ischemic attack or 
cerebrovascular disease, unstable cardiac arrhythmia, or resuscitated sudden cardiac 
death.  
17. Has any solid  tumor malignanc y currently diagnosed or undergoing therapy, or has received 
therapy for any solid tumor malignancy  in the 5 years prior to Screening Visit/Visit  1, with 
the exception of treated and cured bas al cell carcinoma, treated and cured squamous cell 
carcinoma of the skin, and treated and cured carcinoma in situ of the cervix. 
18. Has a diagnosis of, is undergoing therapy for, or has received therapy for a hematologic 
malignancy  in the 5 years prior to Screening Visit/Visit  1. 
19. Has been treated with any of the medications outlined in  Table 2  within the specified 
timeframe prior to the Screening Visit/Visit 1.  
Table 2: Prohibited Medications Relative to Screening Visit/Visit  1 
24 weeks before 
Screening 
Visit/Visit 1  12 weeks before 
Screening 
Visit/Visit 1  8 weeks before Screening 
Visit/Visit 1  4 weeks before Screening 
Visit/Visit 1  
Rituximab  Investigational 
treatment for FSGS  Intravenous/intramuscular 
corticosteroidsa, c Therapeutic drug/device trial 
(except FSGS)  
Cyclophosphamide  Chronic oral 
corticosteroidsa,b   
aDoes NOT include corticosteroids (enteral or parenteral) used for the treatment of FSGS.  
bChronic use is defined as any dose of corticosteroid taken ï€¾ 4 consecutive weeks.  
cAny dose of parenteral corticosteroids 8 weeks prior to Scre ening Visit/Visit 1.  
 
20. Has been treated with any of the medications outlined in  Table 3 within the specified 
timeframe prior to Baseline Visit/Visit 2.  
Table 3: Prohibited Medications Relativ e to Baseline Visit/Visit 2  
FSGS Treatment at Screening Visit/Visit 1a Days Prior to Baseline/Visit 2  
CNI ï€¾ 49 days  
Corticosteroidsb, Mycophenolate, Mofetil  ï€¾ [ADDRESS_1250876] is not currently receiving immunosuppressant treatment for FSGS at the Screening Visit/Visit 1, the 
Baseline Visit/Visit 2 will occur ï€¾2 days and ï€¼ 63 days after the Screening Visit/Visit 1.  
bCorticosteroids used for the treatment of FSGS (see e xclusion Criterion 14 for corticosteroid use to treat other 
conditions).  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 43 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
  
21. Has current or recent (within 6 months of the Screening Visit/Visit 1) drug or alcohol 
abuse as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, 
Diagnostic Criteria for Drug and Alcohol Abuse ( American Psychiatric Association, 
2013 ). 
22. Has any of the fo llowing laboratory abnormalities at the Screening Visit/Visit  1: 
ï€­ Hemoglobin â‰¤ 8.0 g/dL.  
ï€­ Platelets â‰¤ 50,000 cells/Î¼L.  
ï€­ Absolute neutrophil count (ANC) â‰¤ 1,000 cells/Î¼L.  
ï€­ Aspartate  aminotransferase (AST), alanine a minotransferase (ALT), or total 
bilirubin ï€¾ 2 times the upper limit of normal (ULN).  
ï€­ Glycosylated hemoglobin (HbA1c) ï€¾ 6.5%. 
ï€­ Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody 
(HBcAb).  
ï€­ Positive Hepatitis C virus antibody (HCV) and  HCV po lymerase chain reaction 
(PCR) â‰¥  25 IU/mL ( HCV PCR will be automatically analyzed if HCV is 
positive).  
ï€­ Positive or indeterminate interferon gamma release assay (IGRA).  
23. Has any other clinically significant disease, disorder or laboratory abnormality 
(including  those listed on the Prescribing Informa tion Section 5 : Warnings and 
Precautions [ Mallinckrodt ARD  LLC, 2015 ]) which, in the opi[INVESTIGATOR_871] (by 
[CONTACT_630023]), might put the patient at risk due to 
participation in the stu dy, or may influence the results of the study or the subjectâ€™s ability 
to complete the study.  
6.3. Screen Failure  
Subjects will be allowed to repeat any screening procedure once, as long as the results of the 
repeated procedure will be available within the scre ening visit window. This will not be 
considered a screen failure. The period from the start of the screening visit to the baseline visit 
must not exceed [ADDRESS_1250877] who is a screen failure at the Screening Visit /Visit 1 or at the Baseline Visit/Visit [ADDRESS_1250878] 30 days will be recorded.  
In addition, all prior treatments for FSGS will be recorded with start and stop date, dose, unit, 
frequency an d route of administration.  
7.1. Prohibited Concomitant Medications  
The following treatments will not be permitted during the study:  
ï‚· Any long -acting corticotropin other than IMP.  
ï‚· Any enteral or parenteral corticosteroid use (topi[INVESTIGATOR_2855], inhaled and intra -articular 
corticosteroids are allowed).  
ï‚· Administration of live or live -attenuated vaccines.  
ï‚· Enteral or parenteral immunosuppressive medications including, but not limited to 
methotrexate, azathioprine, cyclophosphamide, cyclosporine, tacrolimus, MMF, 
rituximab (or o ther B -cell inhibitors), and tumor necrosis factor inhibitors (eg, 
EnbrelÂ®, HumiraÂ®, RemicadeÂ®); intraocular immunosuppressive medications are 
allowed . 
ï‚· Any investigational drug, device, or procedure administered as part of a research 
study.  
If any prohibited medication is taken during the study, all pertinent information will be recorded 
in source documents and the electronic case report form (eCRF). The designated study MM must 
be informed immediately so the sponsor may determine whether to continu e the subject in the 
study.  
7.2. Permitted During Study  
If any medication is taken during the study, all pertinent information will be recorded in source 
documents and the eCRF.  
Subjects should remain on stable doses of ACEi and/or ARB  during the study . An adj ustment in 
the dose of these medications would represent a protocol deviation, but would not necessarily 
mandate study termination. Adjustments in dose of a concomitant medication should be 
documented in the subjectâ€™s source documents and eCRF.  
8. PROCEDURES  
The schedule of study procedures is summarized in the Schedule of Study Events  (Table 1 ). 
8.1. Screening Visit/Visit 1 (Study Days -63 to -3) Procedures  
Screening assessments must be performed within 3 to 63 days prior to the Baseline Visit/Visit  2. 
The following procedures will be performed at the Screening Visit/Visit 1:  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 45 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Informed consent.  
ï‚· Note: Subjects (US only) with stored renal biopsy samples will be reconsented after 
implementation of Amendment [ADDRESS_1250879] and p ermission for 
additional sample examination.  
ï‚· Inclusion/exclusion criteria.  
ï‚· Contact [CONTACT_410508]/Web Response System (IXRS).  
ï‚· Medical and surgical history.  
ï‚· Current medical condition review.  
ï‚· Demographics.  
ï‚· Vital signs.  
ï‚· Height and Weight.  
ï‚· Complete phy sical examination.  
ï‚· Clinical laboratory tests.  
ï‚·  
ï‚· HbA1c.  
ï‚· Serum pregnancy test.  
ï‚· Hepatitis serology.  
ï‚· IGRA test for TB (to be performed locally).  
ï‚· Urinalysis.  
ï‚·  
ï‚·  
NOTE: A separate consent is required for this procedure.  
ï‚· Dispense 24 -hour urine collection materials.  
ï‚· Adverse events  (AEs) and concomitant medications.  
Subjects who are taking immunosuppressant medication for FSGS at the time of the Screening 
Visit/Visit [ADDRESS_1250880] discontinue their use and complete a washout period of appropriate length 
before the  Baseline Visit/Visit 2 ( Table 4 ).  
Table 4: Timing of Baseline Visit/Visit 2 Relative to FSGS Treatm ent at Screening  
FSGS Treatment at Screening Visit/Visit 1  Timing of Baseline Visit/Visit 2  
CNI ï€¾ 49 days and ï€¼ 63 days after drug discontinuation  
Corticosteroids, MMF  ï€¾ 30 days and ï€¼ 63 days after drug discontinuation  
No treatment  Eligibility is confirmed and IMP is on -site. 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 46 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
  
Subjects will be allowed to repeat any screening procedure, if necessary, if it is within the 
screening time window.  A screening procedure can be repeated only once; if the repeat 
procedure continues to be exclusionary, the subject will be a screen failure.  
8.2. Baseline Visit/Visit 2 Procedures  
The timing of the Baseline Visit/Visit [ADDRESS_1250881] a 24 -hour urine 
3 days pr ior (Â± 2 days) to Baseline Visit/Visit 2.  
The investigator or designee will complete the following procedures at the Baseline Visit/Visit  2:  
ï‚· Inclusion/exclusion criteria review; subject must meet all eligibility criteria at 
Screening Visit/Visit 1 and Baseline Visit/Visit 2.  
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight (height from Visit 1 will be used to calculate BMI at Visit 2).  
ï‚· Clinical laboratory tests.  
ï‚· Nonfasting lipid panel.  
ï‚·  
ï‚· Urine pregna ncy test.  
ï‚· Urinalysis.  
ï‚·  
ï‚·  
  
ï‚·  
 . 
ï‚· Subject diary training.  
ï‚· Contact [CONTACT_893163].  
ï‚· IMP administration under supervision of study staff and observation for at least 1 
hour thereafter.  
ï‚· AEs and concomitant medications.  
8.3. Visit 3 Procedures  (Week 4 Â± 5 Days) 
ï‚· Current medical condition review.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 47 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.4. Visit 4 Procedures (Week 8 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical  examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚·  
ï‚· Urine pregnancy test.  
ï‚· Urinalysis.  
ï‚·  
  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163]. 
ï‚· AEs and concomitant medications.  
8.5. Visit 5 Procedures (Week 12 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 48 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Clinical laboratory tests.  
ï‚· Nonfasting lipid panel.  
ï‚· HbA1c.  
ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_18375], dispense IMP kits.  
ï‚· AEs and concomitant medications.  
8.6. Visit 6 Procedures (Week 16 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚·  
ï‚· Urine pregnancy test.  
ï‚· Urinalysis.  
ï‚· . 
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.7. Visit 7 Procedures (Week 20 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 49 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_630027] s. 
ï‚· Dispense 24 -hour urine collection materials.  
ï‚· AEs and concomitant medications.  
8.8. Visit 8 Procedures (Week 24 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· Nonfasting lipid panel.  
ï‚· HbA1c.  
ï‚·  
ï‚· Urine pregnancy test.  
ï‚· Urinalysis.  
ï‚·  
  
  
ï‚· IMP accountability.  
ï‚·  
  
ï‚· Study diary retraining.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.9. Visit 9 Procedures (Week 26 + 5 Days) 
ï‚· Current medical condition review.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 50 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountabilit y. 
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.10. Visit 10 Procedures (Week 30 Â± 5 Days)  
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.11. Visit 11 Procedures (Week 34 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weig ht. 
ï‚· Clinical laboratory tests.  
ï‚·  
ï‚· Urine pregnancy test.  
ï‚· Urinalysis.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 51 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚·  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.12. Visit 12 Procedures (Week 38 Â± 5 Days)  
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· Nonfasting lipid panel.  
ï‚· HbA1c.  
ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.13. Visit 13 Procedures (Week 42 Â± 5 Days)  
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· . 
ï‚· Urine pregnancy test.  
ï‚· Urinal ysis. 
ï‚·  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 52 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· AEs and concomitant medications.  
8.14. Visit 14 Procedures (Week 46 Â± 5 Days)  
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· Urine pregnancy test.  
ï‚·  
ï‚· IMP accountability.  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_893163].  
ï‚· Dispense 24 -hour urine collection materials.  
ï‚· AEs and concomitant medications.  
8.15. Visit 15 Procedures (Week 50 Â± 5 Days) 
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  
ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests.  
ï‚· Nonfasting lipid panel.  
ï‚· HbA1c.  
ï‚·  
ï‚· Urine pregnancy test.  
ï‚· Urinalysis.  
ï‚·  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 53 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚·  
  
  
  
ï‚· Study diary review.  
ï‚· IMP accountability.  
ï‚· Contact [CONTACT_18375].  
ï‚· AEs and concomitant medications.  
8.16. End of Study/Early Termination Visit Procedures  
All subjects will have an End of Study/Early Termination Visit [ADDRESS_1250882] dose of 
IMP.  
Subjects receiving IMP 3x/week, will have IMP tapered to 2x/week for 2 weeks at Week 50 and 
then discontinued. The se subjects will return at Week 56 + 5 days for their End of Study Visit.  
Subjects receiving IMP 2x/week will discontinue dosing without a taper. These  subjects will 
return at Week 54 + [ADDRESS_1250883] their dose 
tapered to 1 mL SC 2x/week (if required) and return for the Early Termination Visit [ADDRESS_1250884] dose of IMP.  
The following assessment will be done at the End of Study/Early Termin ation Visit  
ï‚· Current medical condition review.  
ï‚· Complete physical examination.  
ï‚· Vital signs, including weight.  
ï‚· Clinical laboratory tests.  
ï‚· Urine pregnancy test.  
ï‚· Urinalysis  
ï‚· IMP accountability (subjects who required taper only).  
ï‚· Study diary review.  
ï‚· Contact [CONTACT_18375].  
ï‚· AEs and concomitant medications.  
8.17. Taper Safety Visit  
ï‚· Current medical condition review.  
ï‚· Limited physical examination.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 54 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Vital signs.  
ï‚· Weight.  
ï‚· Clinical laboratory tests (if the reason for discontinuation was related to laboratory 
test results).  
ï‚· IMP accountabili ty. 
ï‚· Study diary review.  
ï‚· AEs and concomitant medications.  
9. INVESTIGATIONAL MEDI CINAL PRODUCT  
9.1. Methods of Assigning Subjects to Treatment Groups  
The investigator or designee will contact [CONTACT_893164] 1. The subjectâ€™s 
identification (ID) number will be determined by [CONTACT_893165]. Subject ID numbers 
will consist of 7 digits: the first [ADDRESS_1250885] ID number. At the Baseline Visit/ Visit 2, qualified subjects who meet all of the 
eligibility criteria will be enrolled into the study. The investigator or designee must contact [CONTACT_893166].  
The investigator or d esignee must contact [CONTACT_893167] a screen failure if the 
enrolled subject does not meet eligibility criteria at the Baseline Visit/Visit 2.  
The investigator or designee must contact [CONTACT_893168] s. 
The investigator must maintain a subject master log linking the subject ID to the subjectâ€™s name. 
The investigator must follow all applicable privacy laws in order to protect a subjectâ€™s privacy 
and confidentiality. Information that could identify a sub ject will be masked on material received 
by [CONTACT_456].  
9.2. Emergency Identification of Investigational Medicinal Product  
This is an unblinded study.  
9.3. Dosing Procedures  
The following Acthar  treatments are to  be administered . The study treatment schedule is as noted 
in Table 5. 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 55 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Table 5: IMP Treatment Schedule  
Study Week  Study Period  Study Drug  Dose 
Weeks 0 to 50  Open Label/Open -label 
Extension  Acthar  1 mL SC 3x/weeka 
Weeks 50 to 51b Follow -up Period (taper)  Acthar  1 mL SC 2x/week  
aDose can be tapered to 1 mL SC 2x/week for safety and/or tolerability reasons. If a subject ends study participation prior to  
Week 50, the dose of Acthar should be tapered to 1 mL SC 2x/week for 2 weeks.  
bSubjects re ceiving Acthar 1 mL (80 U) SC 3x/week should be tapered to 1  mL SC 2x/week for [ADDRESS_1250886] dose of Acthar. Subjects in the  open -label extension  receiving 1 mL SC 2x/week at Week [ADDRESS_1250887]â€™s caregiver will administer the first dose of IMP in the clinic under the 
supervision of study staff. The subject will remain in the clinic for at least [ADDRESS_1250888] dose to 
monitor for allergic or anaphylactic reaction(s). After Visit 2, all doses will be administered by 
[CONTACT_29159]â€™s caregiver at home.  
Throughout the trial, IMP cannot be taken on 2 consecutive days and cannot be taken more than 
3 days apart, regardless of dosing frequency.  
9.3.1. Dose Reduction  
The dosing of Acthar should be tapered from 3x/week to 2x/week for safety reasons if a subject 
meets any of the following criteria:  
ï‚· Development of accelerated hypertension (defined as systolic bloo d pressure â‰¥ 180 
and diastolic blood pressure â‰¥ 100 mm Hg) that cannot be managed with adjustment 
of concomitant medications such as antihypertensive medications.  
ï‚· Development of an edema score of 4 at any visit that cannot be managed with 
adjustment of con comitant medications such as diuretics (see  Section 24.2). 
ï‚· Development of congestive heart failure that cannot be managed with adjustment of 
concomitant medications such as diuretics and antihypertensive medications.  
ï‚· Development of diabetic signs/s ymptoms (ie, HbA1c ï€¾ 8%, or fasting plasma glucose 
ï€¾ 126 mg/dL, or classic symptoms of hyperglycemia w ith random plasma glucose 
ï€¾ 200 mg/dL).  
ï‚· Development of any other AE of at least moderate intensity that cannot be managed 
with adjustment of concomitant m edications.  
Any s ubject whose dose is tapered for any of the reasons described above will have a Taper 
Safety Visit scheduled 2 weeks after the start of the taper.  
9.3.2. Treatment Discontinuation  
Treatment with Acthar should be discontinued for safety purposes i f the reduction in dosing to 
2x/week and adjustment of concomitant medications does not manage the following:  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 56 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· Persistent accelerated hypertension (defined as systolic blood pressure â‰¥ 180 and 
diastolic blood pressure â‰¥ 100 mm Hg).  
ï‚· Persistent edema score of  4 (see  Section 24.2). 
ï‚· Persistent congestive heart failure.  
ï‚· Persistent diabetic signs/symptoms (ie, HbA1c ï€¾ 8%, or fasting plasma gluco se 
ï€¾ 126 mg/dL, or classic s ymptoms of hyperglycemia w ith random plasma glucose 
ï€¾ 200 mg/dL).  
ï‚· Any other AE of at least moderate intensity that cannot be managed with adjustment 
of concomitant medications.  
The investigator should discontinue subjects for safety purposes any time durin g the study if the 
subject meets any of the following criteria:  
ï‚· Development of unexplained and sustained (2 consecutive visits) worsening of 
disease defined as unresolved progression or 30% decline in eGFR from baseline, or 
if the subjects remains at signi ficant risk of sequelae of nephrotic syndrome (such as 
serum albumin ï€¼ 2.8 mg/dL) and sustained worsening of uPCR ( increase ï€¾ 50% 
from baseline).  
ï‚· Development of ESRD and requirement for chronic renal replacement therapy.  
ï‚· Administration of live or live -attenuated vaccines after Screening Visit/Visit 1.  
ï‚· Diagnosis of a malignancy or lymphoproliferative disorder.  
ï‚· Pregnancy during the course of the study.  
ï‚· Development of an independent disease that requires treatment with 
immunosuppressive therapy or plasma exch ange therapy.  
ï‚· Development of a contraindication to IMP use.  
ï‚· Use of any investigational drug, device, or procedure as part of a research study.  
9.4. Description of IMP  
Acthar is a highly purified sterile preparation of prolonged -release porcine ACTH analogue  in 
16% gelatin for intramuscular or SC injection. Acthar contains 0.5% phenol, not more than 0.1% 
cysteine (added), sodium hydroxide and/or acetic acid to adjust pH, and water for injection. 
Acthar is obtained from processing porcine pi[INVESTIGATOR_410472] a FDA app roved process.  
Acthar is supplied as [ADDRESS_1250889] is assigned. IMP will be stored under refrigeration between 
2Â° to 8Â°C (36Â° to 46Â°F). Please refer to the Pharmacy Manual for complete information regarding 
storage and accountability of IMP.  
9.6. Drug Accountability  
In accordance with ICH requirements, the investigator will, at all times, be able to account for all 
IMP furnished to the study site. A drug accountability record will be maintained for this purpose. 
The investigator must mainta in accurate records indicating dates and quantity of IMP received, 
to whom it was dispensed (subject -by-subject accounting) and accounts of any IMP accidentally 
or deliberately destroyed. All unused IMP not involved in immediate subject dosing will be 
main tained under locked, temperature -controlled storage at the study site.  
9.7. Compliance Monitoring  
Prior to beginning the administration of IMP, subjects and/or their caregiver will be trained on 
dosing administration and must exhibit proper technique. Subjects  and/or their caregiver will be 
trained on the completion of the study diary and will complete a study diary entries to record all 
IMP administration and will bring it, along with all IMP kits including used vials to each visit. 
Each time IMP is dispensed compliance will be encouraged. Subject diary training is an ongoing 
process as the diary will be reviewed with the subject at each visit to monitor compliance with 
IMP administration.  
10. SAFETY ASSESSMENTS A ND PROCEDURES  
The following safety assessments will be evaluated: AEs, physical examinations, clinical 
laboratory test results (chemistry, hematology, HbA1c, , and urinalysis,  
hepatitis serology, IGRA for TB test) and vital signs. All safety assessments will be performed at 
times outli ned in the Schedule of Study Events (Table 1 ). Additional (unscheduled) safety 
assessments may be performed as needed.  
10.1. Adverse Events  
AEs will be collected  from signing of the ICF and followed by [CONTACT_893169].  AEs occurring prior to the administration of IMP will only be reported if 
they are related to study procedures. Any and all safety measures (which includes standard of 
care activities) should be provided by [CONTACT_893170]. Any study site follow -up 
should be documented.  
Refer to Section 13.4 for additional details on the handling of AEs and SAEs.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 58 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 10.2. Medical and Surgical History  
Medical and surgical history will be obtained at the Screening Vi sit/Visit 1. Medical history will 
include a review of the following systems: general, dermatological, respi[INVESTIGATOR_696], cardiovascular, 
gastrointestinal, genitourinary, gynecological, endocrine, musculoskeletal, hematological, 
neuropsychological, immune (allerg ies), and head, eyes, ears, nose, and throat. Historical and 
current medical conditions including date of last menstrual period for female subjects will be 
recorded.  
10.3. Current Medical Conditions  
At each visit after screening, subjects will be asked about an y changes in medical conditions, 
specifically new medical conditions and worsening of existing medical conditions. Any changes 
since the Screening Visit/Visit 1 will be recorded as AEs, as appropriate.  
10.4. Physical Examination s 
A complete physical examination will be performed at the Screening Visit/Visit 1 and the End of 
Study/Early Termination Visit. The complete physical examination includes evaluation of the 
head, eyes, ears, nose, throat, neck (including thyroid), cardiovascular system (including 
assessmen t of heart, peripheral pulses, presence or absence of edema), lungs, abdomen 
(including liver and spleen, bowel sounds), lymph nodes, musculoskeletal system (including 
spi[INVESTIGATOR_050], joints, muscles) neurological system (including cranial nerves, reflexes, sensati on, 
strength), skin, extremities and other conditions of note.  
A limited physical examination, including evaluation of lungs, heart, abdomen, extremities and 
assessment for edema will be done at all other visits.  
The findings of the physical examinations will be recorded. Any change from the Screening 
Visit/Visit [ADDRESS_1250890] has been seated for 5 mi nutes (minimum) and will 
include systolic and diastolic blood pressures, pulse rate, respi[INVESTIGATOR_697], and body temperature. 
Additionally, at the Screening Visit/Visit 1 and the Baseline Visit/Visit 2, blood pressure will be 
measured at least [ADDRESS_1250891] 5 minutes, if possible. Unscheduled vital signs will be 
recorded.  
At a minimum, the date of vital signs at the Screening Visit/Visit 1 will be recorde d. The date 
and time for all other vital signs will be recorded.  
Screening/Baseline  
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250892] with systolic blood pressure ï€¾ 150 mm Hg and diastolic blood pressure ï€¾ 90 mm Hg 
(average of 3 assessments) at the Screening Visit/Visit 1 or Baseline Visit/Visi t [ADDRESS_1250893]â€™s clinical 
management.  
10.6. Height and Weight  
Height will be collected at sc reening only. Weight will be collected at specified times during the  
study.  
10.7. Clinical Laboratory Tests, HbA1c, Serum Cystatin C, Serum 
Electrolytes,IGRA, Urinalysis, and Pregnancy Tests  
The clinical laboratory tests are listed in Section 24.1. All clinical laboratory tests will be done at 
a central laboratory facility except urine pregnancy (at the site) and IGRA (local laboratory). 
Specific instructions for collection, storage an d shipment of clinical laboratory samples will be 
provided in a separate laboratory manual.  
Samples for laboratory testing at all visits may be collected under fasted or nonfasted conditions. 
The date and time of the sample collection must be documented on  the laboratory report. 
Investigators must review and sign laboratory reports. The clinical significance of each 
laboratory abnormality will be documented. New clinically significant laboratory abnormalities 
or clinically significant changes in laboratory values will be reported as AEs, as appropriate.  
Hematology with differential, serum chemistry, other specific tests, and urinalysis samples will 
be collected at the specific times starting at screening and throughout the study.  
In addition:  
ï‚· All female subj ects of child -bearing potential will have a serum pregnancy test at the 
Screening Visit/Visit 1, and a urine pregnancy test at the Baseline Visit/Visit [ADDRESS_1250894] be available prior to dosing with 
protocol mandated IMP. Subjects with positive results will be ineligible for study 
entry (Screening Visit/Visit 1) or withdrawn from the study. Any female subject that 
becomes pregnant during the study will be immediately withdrawn and the pregnancy 
report as per Section 13.5. 
If applicable, the subjectâ€™s agreement to use contraception throughout their study 
participation, and for 4 weeks after ending study participation, wi ll be documented.  
ï‚· HBsAg and HBcAb will be performed at the Screening Visit/Visit 1. Results of these 
tests must be negative or nonreactive for subjects to qualify for the study.  
ï‚· HCV will be performed at the Screening Visit/Visit 1. A positive HCV will 
automatically trigger a HCV PCR analysis. HCV PCR must be ï€¼ 25 IU/mL to qualify 
for the study.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 60 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 ï‚· IGRA for TB will be performed at the Screening Visit/Visit 1. Results of this test 
must be negative for subjects to qualify for the study.  
ï‚· HbA1c.  
ï‚· Non-fasting lipid  panel including total cholesterol, high density lipoprotein (HDL), 
low density lipoprotein (LDL), and triglycerides.  
ï‚·  
Out-of-range Laboratory Values  
Laboratory values from samples collected at the Screening Visit/Visit [ADDRESS_1250895] in the study.  
Laboratory values that fall outside the reference range from samples collected during the study or 
at study exit or early termination will be assessed by [CONTACT_893171] s ignificance. If 
the out of range value for samples is deemed clinically significant by [CONTACT_093], an AE will 
be recorded.  
11. EXPLORATORY  ASSESSMENTS  
The following exploratory  assessments will be evaluated at times specified in the Schedule of 
Study Eve nts (Table 1 ). 
  
  
 
 
 
 
 
 
 
 
 
 
 
  
. 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 61 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
   
  
 
 
 
 
 
 
  
 
 
 
 
   
 
 
 
  
 
 
  
 
 
 
 
12. STATISTICAL METHODS AND PLANNED ANALYSIS  
12.1. General Considerations  
Data will be listed, analyzed, and included in the clinical study report. Data will be analyzed as 
described in the statistical analysis plan. Descriptive statistics for continuous variables will 
include number of values, mean, SD, median, minimum, and maximum,  unless otherwise noted. 
Frequency and percentages will be calculated for categorical variables. All statistical significance 
testing will be 2 -tailed using Î± = 0.05, unless otherwise specified. Data summary and analyses 
will be performed with SAS 9.2 or h igher.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 62 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 12.2. Analysis Populations  
ï‚· The Intent  to Treat (ITT) Population will include all enrolled subjects who receive 1 or 
more doses of IMP and who contribute any exploratory  data to the study.  
ï‚· The Per Proto col Population will include the subset of the ITT population who 
complete  the study as per protocol. Completer populations will be further defined in 
the statistical analysis plan.  
ï‚· The Safety Popu lation will include all enrolled subjects who receive 1 or more doses of 
IMP. 
12.3. Efficacy Assessments  
12.3.1. Primary Efficacy Endpoint  
There is no primary efficacy endpoint.  
12.3.2. Secondary Efficacy Endpoints  
There are no secondary efficacy endpoints.  
12.4. Primary Safety Endpoints  
The primary safety endpoints to be evaluated include a summary of the general safety profile 
including AEs (serious and non -serious), physical examinations, clinical laboratory tests, vital 
signs, medical and surgical history, height and height.   
12.5. Explorato ry Endpoints  
Exploratory endpoints will examine  
 
 
 
  
   
  
  
 
  
 
  
 
 
 
  
 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 63 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
    
  
 
Exploratory endpoints include:  
  
  
  
  
  
  
  
   
  
   
  
  
  
  
12.6. Subject Characteristics  
12.6.1. Demographics  
All dosed subjects enrolled in the study will be included in a listing of subject demographic 
characteristics. Summary statistics tables will present the data for all dosed subjects combined as 
well as for completers only.  
12.6.2. Medical and Surgical History  
The medical and surgical history data will not be summarized but will be presented in a data 
listing.  
12.6.3. Concomitant Medications  
Concomitant medications will  not be summarized but will be presented in a data listing.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250896] 1 dose of IMP will be included in the safety analyses.  
12.7.1. Adverse Events  
AEs will be coded using MedDRA. All A Es will be presented in a data listing. Only treatment -
emergent adverse events (TEAEs) will be included in all summaries.  
TEAEs, treatment related TEAEs, severity of TEAEs, and TEAEs leading to early 
discontinuation will be summarized by [CONTACT_893172]. All TEAEs leading to early discontinuation will be 
presented in data listings.  
12.7.2. Clinical Laboratory Tests  
Clinical laboratory testing will be presented in data listings.  
12.7.3. Physical Examination Findings  
All physical examination results will be presented in a data listing.  
12.7.4. Vital Signs/Height and Weight  
Vital sign measurements (diastolic blood pressure, systolic blood pressure, respi[INVESTIGATOR_697], pulse 
rate, body  temperature, weight and height) will be presented in a data listing.  
12.8. Interim Analysis  
Not applicable.  
12.9. Statistical Power and Sample Size Consideration  
Formal sample size calculations were not performed.  
12.10. Deviations From Statistical Analysis Plan  
Any deviati ons from the planned statistical analysis will be described and justified in the final 
clinical study report as appropriate.  
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250897] recent version of the Prescr ibing 
Information ( Mallinckrodt ARD  LLC, 2015 ). 
13.2. Definitions  
Adverse Event  
An AE is any untoward or undesirable medical occurrence in a subject who is administered an 
IMP, which does not necessarily have to have a ca usal relationship with this treatment. Examples 
of AEs include but are not limited to:  
ï‚· Clinically significant laboratory findings.  
ï‚· Clinically significant changes in physical examination findings.  
ï‚· An AE occurring due to IMP overdose whether accidental or in tentional.  
ï‚· An AE occurring from IMP abuse.  
ï‚· An AE associated with IMP withdrawal.  
ï‚· Unexpected AE. 
An unexpected AE is defined as an AE, the nature and severity of which is not consistent with 
the applicable product information in the most recent version of t he Investigatorâ€™s Brochure.  
Serious Adverse Event  
A serious adverse event  (SAE ) is defined as any untoward medical occurrence that at any dose 
results in any of the following outcomes:  
ï‚· Death.  
ï‚· A life -threatening AE.  
ï‚· Inpatient hospi[INVESTIGATOR_29350].  
ï‚· A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions.  
ï‚· Results in a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life-threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, may 
jeopardize the subject or subject and may require medical or surgical intervention to prevent one 
of the outcomes listed above. Exampl es of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency department or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug 
dependency or drug abus e. 
Death 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250898] caused death but, as it actually occurred, did not create an immediate risk of death. 
For example, hepatitis that resolved without evidence of hepatic failure would not be considered 
life-threatening, even though hepatitis of a more severe nature can b e fatal. Similarly, an allergic 
reaction resulting in angioedema of the face would not be life -threatening, even though 
angioedema of the larynx, allergic bronchospasm, or anaphylaxis can be fatal.  
Hospi[INVESTIGATOR_155555] a hospi[INVESTIGATOR_307]. Hospi[INVESTIGATOR_155556] a hospi[INVESTIGATOR_155557] a criterion for an AE to be serious; however, it is not in itself 
considered an SAE. In absence of an AE, a hospi[INVESTIGATOR_17127] a hospi[INVESTIGATOR_893146] d not be reported by [CONTACT_477573]. Such situations include, but are not limited 
to, the following:  
ï‚· A hospi[INVESTIGATOR_112041] a procedure required 
by [CONTACT_760].  
ï‚· A hospi[INVESTIGATOR_17127] h ospi[INVESTIGATOR_893147] a routine procedure 
followed by [CONTACT_16018] (eg, stent removal after surgery). This should be recorded in 
the study file.  
ï‚· A hospi[INVESTIGATOR_272] a preexisting condition that has not worsened.  
Note that a visit to the emergency depar tment or other hospi[INVESTIGATOR_477552] 24 hours 
that does not result in admission (unless considered "important medical event" or life -threatening 
event)  is not considered an SAE in Mallinckrodt clinical studies . 
13.3. Adverse Event and Serious Adverse Event Classifications  
IMP Relatedness  
The following classifications should be used when evaluating the relationship of AEs or SAEs to 
study treatment (Table 7 ). 
Table 7: Adverse Event Relatio nships 
Relationship  Definition  
Not Related  No relationship between the experience and the administration of study treatment; related 
to other etiologies such as concomitant medications or subjectâ€™s clinical state.  
Unlikely Related  The current state of knowledge indicates that a relationship is unlikely.  
Possibly Related  A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to the suspected study treatment. The 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250899]â€™s clinical state or other modes of 
therapy administered to the subject.  
Related A reaction that follows a plausible temporal sequence from administration of the study 
treatment and follows a known response pattern to th e suspected study treatment and can 
be confirmed with a positive re -challenge test or supporting laboratory data.  
 
Severity Assessment  
For purposes of consistency, if required the investigator may use the intensity grades presented 
in Table 8 . 
Table 8: Adverse Event Severity Grades  
Grade Definition  
Mild Does not interfere with subject's usual function and activities  
Moderate  Interferes to some extent with subject's usual function and activities  
Severe Interferes significantly with subject's usual function and activities  
 
If an AE increases in severity (eg, from moderate to seve re); decreases in severity (eg,  changes 
from moderate to mild); or there is a change in seriousness, a new A E will be opened and the 
original AE will be closed. If an AE is still ongoing at the time of a subjectâ€™s completion of the 
follow -up visit, the resolution/stop date and time is left blank.  
To ensure there is no confusion or misunderstanding of the difference between the terms 
â€œseriousâ€ and â€œsevere,â€ which are not synonymous, the following note of clarification is 
provided:  
The term â€œsevereâ€ is used to describe the intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial i nfarction); the event itself, however, may be of relatively minor 
medical importance (such as a severe headache). This is not the same as â€œserious,â€ which is 
based on the subject/event outcome or action criteria usually associated with events that pose a 
threat to a subject's life or functioning. Seriousness (not severity) serves as a guide for defining 
regulatory reporting obligations.  
13.4. Adverse Event and Serious Adverse Event Recording and Reporting  
AEs and SAEs will be collected  from signing of the ICF thr ough completion of the end of 
study/early termination  visit. All AEs and SAEs should be recorded in source documents; all 
AEs and SAEs that occur following the first dose of IMP should also be recorded in the eCRF. 
The investigator is required to record th e AE or SAE regardless of the severity of the event or its 
relationship to study treatment. Prior to the first dose at the Baseline Visit/Visit 2, only AEs and 
SAEs related to study procedures will be recorded  on the eCRF . The investigator must follow up 
on all AEs and SAEs reported to have occurred [ADDRESS_1250900]â€™s 
source document.  
During the period specified above, the investigator will:  
ï‚· Record all AEs and SAEs from the signing of the ICF through the completion of the 
End of Study/Early Termination visit  
ï‚· Report all SAEs on an SAE Report Form t o Global Pharmacovigilance.  
ï‚· Report all pregnancies to Global Pharmacovigilance on the Pregnancy Surveillance 
Form.  
ï‚· Submit any Expedited Safety Report or Suspected Unexpected Serious Adverse 
Reaction from Global Pharmacovigilance to the IRB/IEC.  
The reporti ng requirements for AEs are summarized in  Table 9 . 
Table 9: Reporting Requirements for Adverse Events  
Seriousness  Reporting Time  Type of Report  
All Serious  Within [ADDRESS_1250901] knowledge  
of event  Initial report on the SAE Form, appropriate 
eCRF, and source document  
Within 24 hours of receipt of follow -
up information  Follow up report on the SAE Form, 
appropriate eCRF, and source document  
Nonserious  Per case report form submission 
procedure  Appropriate eCRF and source document  
 
Adverse Events  
AEs can be reported spontaneously or elicited during open -ended questioning (ie, "How have 
you been feeling since your last visit?"), examination, or evaluation of a subject. Signs and 
symptoms must be recorded using standard medical terminology. For subjects  incapable of 
giving consent, the legally acceptable representative may provide information regarding the 
subjectâ€™s status.  
All fields on the AE CRF page should be completed for each event with a full description of the 
event and date of onset/start and re solution/stop. A medical diagnosis if known, should be 
recorded in lieu of each individual sign and symptom associated with the diagnosis and 
experienced by [CONTACT_423]. If no medical diagnosis is known, the term used by [CONTACT_893173] o r signs noted by [CONTACT_893174].  
Serious Adverse Events  
Initial Reporting  
SAEs (based on FDA/ICH definition of an SAE) require immediate reporting to Global 
Pharmacovigilance.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3    Page 69 of 79 
CONFIDENTIAL AND PROPRIETARY  ï‚·For all SAEs, the investigator, or designee, must complete the SAE Report Form with 
the minimum information required by [CONTACT_893175] 
+1 
[PHONE_8485] or email at [EMAIL_17029]  within [ADDRESS_1250902] knowledge of 
the event even if the experience does not appea r to be related to the IMP.
ï‚·The investigator, or designee, will receive acknowledgement of receipt of the SAE
report form from Mallinckrodt.
ï‚·Should the investigator or designee have any difficulty in sending the SAE report,
they ma y contact [CONTACT_893176].
ï‚·If there is any doubt about whether the information constitutes an SAE, the
information is to be treated as an SAE.
The investigator(s) or designee is required to submit the any expedited safety report or suspected 
unexpected serious adverse reaction to the responsible IRB/IEC.  
The sponsor will ensure that any expedited safety report or suspected unexpected serious adverse 
reaction  are submitted to the FDA and other regulatory a gencies as appropriate.  
Follow Up Reporting 
The investigator or designee must complete an SAE report form for all follow -up information 
received and fax it to Mallinckrodt at +1  [PHONE_8485] within 24 hours of receipt. 
The investigator(s) or designee will  receive acknowledgement of receipt for each SAE report 
form from Mallinckrodt.  
ï‚·The investigator or designee is required to provide all related information/supporting
documentation of an SAE until the SAE is resolved or stabilized or the subject has
been r eferred to a nonstudy physician for follow -up treatment.
ï‚·The investigator(s) or designee is required to submit the safety alert to the responsible
IRB/IEC.
ï‚·The sponsor will ensure that any expedited safety report or suspected unexpected
serious adverse r eaction  are submitted to the FDA and other regulatory agencies as
appropriate.
13.5. Pregnancy Reporting  
Certain information, although not considered an SAE, must be recorded, reported, and followed 
up as indicated.  This includes the following:  
Pregnancy exposure to an investigational medicinal product, except for exposure to prenatal 
vitamins. Subjects should not become pregnant during the study . If the subject becomes 
pregna
nt, study treatment must be disconti nued immediately. The investi gator must report the 
pregnancy by [CONTACT_893177] (fax at [PHONE_10010]- 
5759 or email at [EMAIL_17029]  within 24 hours of confirmation of a pregnancy (ie, 
positive serum pr
egnancy test result). The outco me of pregnancy (eg, spontaneous abortion, live 
birth, still birth, congenital anomalies, birth defects) must be reported by [CONTACT_893178]1422  
Protocol MNK14224049 Amendment 3    Page 70 of 79 
CONFIDENTIAL AND PROPRIETARY  appropriate form to Global Pharmacovigilance (fax at +[PHONE_8484] or email at  
[EMAIL_17029]  within [ADDRESS_1250903] be reported to Global Pharmacovigilance (fax at +1 
[PHONE_8485] or email at [EMAIL_17029]) within [ADDRESS_1250904] 
the Pregnancy Notification form and the Pregnancy Report Fax cover page to Global 
Pharmacovigilance (fax at +[PHONE_8484] or email at [EMAIL_17029]), within 24 hours 
of being notified. The outcome of pregnancy (eg, spontaneous abortion, live birth, still birth, 
congenital anomalies, birth defects) must be reported by [CONTACT_893179] (fax at +[PHONE_8484] or email at  [EMAIL_17029]
) within 
[ADDRESS_1250905] be reported to Mallinckrodt Pharmacovigilance (fax at +[PHONE_8484] or email at 
[EMAIL_17029]) within [ADDRESS_1250906] the end of study/early termination safety assessments 
(see Section 8.16) to assess their continued well -being.  
The reason for discontinuation will be recorded. A subject may be discontinued from the study 
for the following medical or administrative reasons:  
Withdrawal by [CONTACT_893180]. Subjects who have received at 
least [ADDRESS_1250907] develops a condition that meets any of the exclusion criteria ( Section 6.2) or fails to 
meet an inclusion criteria ( Section 6.1) during the study that is not considered to be an AE or is 
noncompliant (eg, has a positi ve pregnancy or drug screening test), the subject will be 
discontinued from further participation in the study. Discontinuation is also mandated for safety 
and/or tolerability issues as outlined in Section 9.3.2 ). 
Other 
If the above reasons are not applicable, please use the â€œOtherâ€ option and provide the appropriate 
reason for subject withdrawal.  
For subjects who discontinue or are withdrawn from the study for any reason, the investigator 
will notify the sponsor and when possible, the subject will be required to have the early 
termination safety assessments ( Section 8.16) to assess their continued well -being.  
15. STUDY SUSPENSION, TE RMINATION, AND COMPL ETION
The sponsor may suspend or terminate the study or part of the study at any time for any reason . 
If the investigator suspends or terminates the study, the investigator will promptly inform the 
sponsor and the IRB/IEC and provide them with a detailed written explanation. Upon study 
completion, the investigator will provide the sponsor, IRB/IEC, and r egulatory agency with final 
reports and summaries as required by [CONTACT_19124]. Study termination and follow -up will be 
performed in compliance with Mallinckrodt standard operating procedures.  
16. PROTOCOL AMENDMENTS
Any change in the study plan requires a prot ocol amendment. An investigator must not make any 
changes to the study without IRB/IEC and sponsor approval except when necessary to eliminate 
apparent immediate hazards to the subjects. A protocol change intended to eliminate an apparent 
immediate hazard to subjects may be implemented immediately, but the change must then be 
documented in an amendment, reported to the IRB/IEC within [ADDRESS_1250908] source documents.  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 72 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 17.1. Study and Study Site Discontinuation Criteria  
The sponsor, investigator, or local and national regulatory authorities may discover conditions 
during the study that indicate that the study or study site should be terminated.  This action may 
be taken after appropriate consultation between the sponsor and investigator. Conditions that 
may warrant termination of the study/study site include, but are not limited to:  
ï‚· The discovery of an unexpected, serious, or unacceptable risk to  the subjects enrolled 
in the study.  
ï‚· The decision on the part of the sponsor to suspend or discontinue testing, evaluation 
or development of the IMP.  
ï‚· Failure of the investigator to enroll subjects into the study at an acceptable rate.  
ï‚· Failure of the invest igator to comply with pertinent regulations.  
ï‚· Submission of knowingly false information from the study site to the sponsor, study 
monitor, or local and national regulatory authorities.  
ï‚· Insufficient adherence to protocol requirements.  
ï‚· Study/study site termination and follow -up will be performed in compliance with 
Mallinckrodt standard operating procedures.  
18. DIRECT ACCESS, DATA HANDLING, AND RECORD -KEEPI[INVESTIGATOR_1645]  
18.1. Investigator  
The investigator will permit study -related monitoring, audits, IRB/IEC review, and regu latory 
inspections by [CONTACT_155608].  
All subject information will be recorded on source documents. The eCRFs must be fully 
completed and include all required data for all subjects enrolled. All eCRF data must  be 
submitted to the sponsor throughout and at the end of the study.  
If an investigator retires, relocates, or otherwise withdraws from conducting the study, the 
investigator must notify the sponsor to agree upon an acceptable storage solution. Regulatory 
agencies will be notified with the appropriate documentation.  
Any significant changes in study personnel will require an updated Statement of Investigator (ie, 
FDA form 1572) to be filed with the sponsor.  
The investigator must notify their IRB/IEC of proto col deviations in accordance with local 
regulatory and IRB/IEC requirements.  
18.2. Sponsor 
The eCRF data are stored in a database and processed electronically. The sponsorâ€™s medical 
monitor  reviews the data for safety information. The data are reviewed for compl eteness, and 
logical consistency. Automated validation programs will identify missing data, out -of-range data, 
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment [ADDRESS_1250909]â€™s medical insurance, a government program, or other responsible third party. If laws 
or regulations of the locality in which the study is taking place require addi tional payment of 
expenses, the sponsor shall comply with such laws or regulations. Where applicable, the sponsor 
has taken specific national insurance.  
20. RECORDS RETENTION  
The investigator shall retain and preserve [ADDRESS_1250910]. These documents should be 
retained for a longer period, however, if required by [CONTACT_155610]. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained. Prior to 
destruction of any study essential documents, the investigator must first obtain written approval 
from the sponsor.  
21. BIOLOGICAL SAMPLES  
Blood and tissue samples will be used only for scientific research. Each sample will be labeled 
with a code so that the lab oratory personnel testing the samples will not know the subjectâ€™s 
identity. After the study ends, the clinical laboratory samples will be destroyed, with the 
exception of urine and serum samples for   
 The subject 
may request that his or her samples, if still identifiable, be destroyed at any time; however, any 
data already collected from that sample will still be used  for this research.  
22. PUBLICATION POLICY  
22.1. Sponsorâ€™s Publication Policy  
The sponsorâ€™s policy is to publish or otherwise communicate the results of its hypothesis -testing 
clinical studies, regardless of outcome, for marketed products, compound(s) or product(s) being 
investigated that are later approved for marketing. Hypothesis -testing clinical studies are those 

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 74 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 studies intended to provide meaningful results by [CONTACT_893181], thereby [CONTACT_893182]/or efficacy to support product claims.  
Exploratory studies, in contrast, serve to set direction for possible future studies. They have 
significant statistical limitations, provide only preliminary information about a dis ease, 
condition, or product, and are not designed to provide final conclusions on product claims. The 
sponsor does not commit to publish or otherwise communicate the results of every exploratory 
study, because this information is of an exploratory nature a nd often highly proprietary. 
However, if information from an exploratory study is of significant medical importance, the 
sponsor will publish or otherwise communicate the results.  
The sponsorâ€™s decision to publish or otherwise publicly communicate the resu lts of this study 
will be made in accordance with all applicable laws, regulations, and sponsor policies regarding 
publication and communication of clinical study results.  
22.2. Investigatorâ€™s Ability to Publish  
Terms and provisions of publication rights are gov erned by [CONTACT_893183].  
23. REFERENCES  
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders  
(5th Edition). 2013 . Washington, DC.  
Barisoni L, Schnaper HW, Kopp JB.  A Proposed Taxonomy for the Podocytopathies: A 
Reassessment of the Primary Nephrotic Diseases. Clin. J. Am. Soc. Nephrol . 2007 , 2, 529 -542. 
Berg AL, Arnadottir M.  ACTH -induced improvement in the nephrotic syndrome in patients 
with a variety of diagnoses. Nephrol. Dial. Transplant . 2004 , 19, 1305 â€“1307.  
Berg AL, Dolinina, Bakoush O.  Treatment of focal segmental glomerulosclerosis with ACTH. J. 
Am. So.c Nephrol. 2012, 23, 941A. 
Bomback  AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, et al.  Treatment of nephrotic 
syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des. Devel. Ther . 2011 , 5, 147 â€“
153. 
Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, et al.  Treatment of resistant 
glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am. J. Nephrol . 
2012 , 36, 58 â€“67. 
Bose B, Cattran D.  Toronto Glomerulonephritis Registry. Glomerular Diseases: FSGS. Clin. J . 
Am. Soc. Nephrol . 2014, 9, 626 -632. 
Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, et al.  Cyclosporin in idiopathic 
glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney 
Int. 2007 , 72, 1429 -47. 
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 75 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Dâ€™Agati  VD, Kaskel FJ, Falk RJ . Focal Segmental Glomerulosclerosis. N. Engl. J. Med . 2011 , 
365, 2398 -2411.  
Getting  SJ. Targeting melanocortin receptors as potential novel therapeutics. Pharmacol. Ther . 
2006 , 111, 1 -15. 
Gong R, Dworkin LD.  ACTH (Acthar gel) prevents proteinuria and ren al injury in the remnant 
kidney: evidence for direct podocyte protection. J. Am. Soc. Nephrol . 2010 , 21, 548A.  
Hladunewich  MA, Cattran D, Beck LH, Odutayo A, Sethi S, et al.  A pi[INVESTIGATOR_893148] (H.P. ActharÂ® Gel) in nephrotic 
syndrome due to idiopathic membranous nephropathy. Nephrol. Dial. Transplant . 2014 , 29, 
1570 -1577.  
Hogan  J, Bomback AS, Mehta K, Canetta PA, Rao MK, et al.  Treatment of idiopathic FSGS 
with adrenocorticotropic hormone ge l. Clin. J. Am. Soc. Nephrol . 2013 , 8, 2072 -2081.  
Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: 
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int . [ADDRESS_1250911] 2, 139 -274. 
Kitiyakara  C, Kopp JB, Eggers P.  Trends in the epi[INVESTIGATOR_893149]. Semin. Nephrol . 2003 , 23, 172 -182. 
Korbet  SM. Clinical pi[INVESTIGATOR_168179]. 
Nephrol. Dial. Transplant.  1999 , 14, 68 -73. 
Lal R, Bell S, Challeng er R, Hammock V, Nyberg M, et al.  Pharmacodynamics and tolerability 
of repository corticotropin injection in healthy human subjects: a comparison with intravenous 
methylprednisolone. J. Clin. Pharmacol.  [ADDRESS_1250912] A, et al.  Melanocortin 1 
receptor agonists reduce proteinuria. J. Am. Soc. Nephrol . 2010 , 21, 1290 -1298.  
Malaga -Diequez  L, Bouhassira D, Bipson D, Trachtman H.  Novel therapi[INVESTIGATOR_893150]: 
preclinical and clinical studies. Adv. Chronic Kidney Dis . 2015 , 22, e1 -e6. 
Wright D. Summary Report: In Vitro Binding Affinity (IC50) and Agonist Effects (EC50) of 
Acthar for Melanocortin Receptors.  Mallinckrodt ARD LLC, Bedmin ster NJ . [ADDRESS_1250913] LLC. H.P. ActharÂ® Gel ; Package Insert: Hazelwood, MO,  2015 . 
SchiÃ¶th  HB, Muceniece R, Wikberg JE, Chhajlani V.  Characterization of melanocortin receptor 
subtypes by [CONTACT_410534]. Eur. J. Pharmacol.  1995 , 15, 3 11-317. 
Troyanov  S, Wall CA, Miller JA, Scholey JW, Cattran DC.  Toronto Glomerulonephritis Registry 
Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. 
J. Am. Soc. Nephrol . 2005 , 16, 1061 -1608.  
  
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 76 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 24. ATTACHMENTS  
24.1. Attachment 1: Clinical Laboratory Tests  
 
Serum Chemistry  
Alanine aminotransferase (ALT)  Creatinine  
Albumin (total)  Cystatin C  
Alkaline phosphatase  Glucose  
Aspartate aminotransferase (AST)  Hemoglobin A1c  
Bilirubin (total)  Phosphorus  
Blood urea nitrogen  Potassium  
Calcium Protein, total  
CO 2 Sodium  
Chloride Uric acid  
  
Lipid Panel  
Total cholesterol  LDL  
HDL  Triglycerides  
  
Hormones  
Serum and urine beta -human chorionic gonadotropin (pregnancy test)  
 
Hematology Assays  
Hematocrit  Platelet count  
Hemoglobin  Red blood cell count  
White blood cell count, including differential  Absolute neutrophil count  
 
Urinalysis  
Blood Nitrite  
Clarity Nitrite  
Color Protein  
Glucose pH 
Leukocyte esterase  Specific gravity  
Ketones   
Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 77 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Serum Chemistry  
  
 
 
 
 
Hepatitis Serology  
Hepatitis B core antibody  Hepatitis C virus antibody (HCV)  
Hepatitis B surface antigen  Hepatitis C virus PCR (only if HCV +)  
TB Assay  
Interferon gamma release assay (IGRA) (obtained at local lab)  
 
 
 
24.2. Attachment 2: Evaluation of Edema  
The presence  of edema will be assessed  using  the following  guidelines.  Firm pressure  should  be 
applied  by [CONTACT_893184] 5 to 10 seconds  over a bony area. 
Evaluation of Edema  
Score* 0 1 2 3 4 
Depth of pit  None  0-2mm  2-4 mm  4-6 mm  6-8 mm  
Description of 
pit none  slight pi[INVESTIGATOR_893151]  10-15 
seconds  1-2 minutes  > 2 minutes  
Visible 
distortion  none  none  none readily  
detectable  dependent  
extremity 
appears fuller 
and swollen  dependent  
extremity is 
grossly distorted  
*Assessment  Chart  for Pi[INVESTIGATOR_893152].  
 
Edema should  also be categorized  as 1 or more of the following  types: 
Categorization of Edema  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 78 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 Type Presacral  Anasarca  Brawny 
Localization  pelvis  general  skin 
Edema evaluated as above  generalized  accompanied by  
[CONTACT_893185]  
  
 
24.3. Attachment 3: Secondary Causes of FSGS  
 
1. Familial  a. Mutations in  
b. Mutations in  
c. Mutations in  
d. Mutations in  
e. Mutations in  
f. Mutations in  
g. Mutations in  
h. Mutat ions in  
i.  
2. Virus associated  
 a. HIV -associated nephropathy  
b. Parvovirus B19  
3. Medication  
 a. Heroin -nephropathy  
b. Interferon -a 
c. Lithium  
d. Pamidronate/alendronate  
e. Anabolic steroids  
4. Adaptive structural -functional responses likely 
mediated by  4.1 Reduced kidney mass  
a. Oligomeganephronia  
b. Unilateral kidney agenesis  
c. Kidney dysplasia  
d. Cortical necrosis  
e. Reflux nephropathy  
f. Surgical kidney ablation  
g. Chronic allograft nephropathy  
h. Any advanced kidney disease with reduction in 
functioning nephrons  
4.2 Initially normal kidney mass  
a. Diabetes mellitus  
b. Hypertension  
c. Obesity  

Mallinckrodt ARC LLC  
MNK1422  
Protocol MNK14224049 Amendment 3                                                                              Page 79 of 79 
 
CONFIDENTIAL AND PROPRIETARY  
 1. Familial  a. Mutations in  
b. Mutations in  
c. Mutations in  
d. Mutations in  
e. Mutations in  
f. Mutations in  
g. Mutations in  
h. Mutat ions in  
i.  
d. Cyanotic congenital heart disease  
e. Sickle cell anemia  
5. Malignancy   
6. Nonspecific pattern of FSGS caused by [CONTACT_893186]  a. Focal proliferative glomerulonephritis 
(IgA  nephropathy, lupus nephritis, pauci -immune focal 
necrotizing and crescentic glomerulonephropathy)  
b. Hered itary nephritis (Alport syndrome)  
c. Membranous glomerulopathy  
d. Thrombotic microangiopathy  
Source: Adapted from Barsoni et al, 2007 . 
